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Summary 
 
A substantial number of psychiatric patients do not benefit from chronic 
antidepressant treatment. To identify biochemical pathways that can stratify 
antidepressant response sub-groups, DBA/2J mice were subjected to paroxetine 
administration for 28 days and classified into drug responder and non-responder 
groups based on floating time during the forced swim test (FST). Hippocampal 
metabolome and proteome profiles were analyzed and integrated to identify 
significant molecular pathway differences between paroxetine-responding and non-
responding animals. I identified metabolites and proteins involved in purine and 
pyrimidine metabolism pathways whose levels were significantly different between 
paroxetine responding and non-responding mice. In addition, the glutamate/ubiquitin 
proteasome system (UPS)-associated pathways were associated with the chronic 
paroxetine treatment response. Specifically, N-Methyl-D-aspartate (NMDA) receptor, 
postsynaptic density protein 95 (PSD-95), and neuronal nitric oxide synthase (nNOS) 
levels significantly correlated with FST floating time suggesting their potential role in 
the antidepressant treatment response. The results from mice were further 
corroborated in human peripheral blood mononuclear cells (PBMCs) of major 
depressive disorder (MDD) patients. Protein signatures including ATIC, CPS2, 
PM2A, sGC-β1 and protein ubiquitination significantly correlated with clinical 
antidepressant treatment response. In my thesis project I have identified affected 
pathways and biomarker candidates related to the heterogeneous antidepressant 
treatment response using integrated -omics analyses combined with sub-group 
stratification based on behavioral phenotyping.  
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1. Introduction 
 
Major depressive disorder (MDD) is one of the most common psychiatric disorders 
which is characterized by persistent decrease/loss of interest and low mood  (Hori et 
al., 2016). The World Health Organization estimates 350 million people suffer from 
MDD. MDD is often associated with suicide attempts and ranked second for glocal 
disease burden (Beautrais et al., 1996; Murray and Lopez, 1997). 
 
1.1. Neuroanatomy of major depressive disorder 
Several brain regions involved in cognitive and emotional processing have been 
shown to be affected in MDD (Figure 1). 
 
 
Figure 1. Brain regions affected in MDD.  
 
The prefrontal cortex is part of the limbic system that controls emotional and 
cognitive functions. The association of prefrontal cortex with mood disorders has 
been extensively studied in animals and humans. Chronic stress has been shown to 
cause dendritic spine atrophy in rodents (Qiao et al., 2016). Prefrontal cortex 
dysfuction has been implicated in depressed patients (Merriam et al., 1999; Murray et 
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al., 2011). Structural atrophy has been shown in the prefrontal cortex of depressed 
patients (Drevets et al., 1997; Bremner et al., 2002). 
Hippocampal volume loss and structural atrophy have been frequently reported in 
MDD patients (Sheline et al., 1996; 1999; Campbell et al., 2004; Opel et al., 2014). In 
the hippocampus adult neurogenesis takes place and this process plays important roles 
in various brain functions including synaptic plasticity, learning and memory, and 
emotional regulation (Jun et al., 2012). Hippocampal adult neurogenesis has been  
associated with MDD pathology and antidepressant treatment response (Malberg et al., 
2000; Anacker et al., 2011; Lee et al., 2013; Mahar et al., 2014; Rotheneichner et al., 
2014). 
Nucleus accumbens (NAc) has also been strongly associated with stress-related 
neuropsychiatric conditions. Chronic mild stress was shown to induce decreased 
dopamine D2 receptor expression in the NAc (Papp et al., 1994). Altered serotonin 
and dopamine turnover was shown in the Flinders sensitive line, a rat model of 
depression (Zangen et al., 1999; 2001). Reduced NAc activity and volume have been 
reported in patients with mood disorders (Baumann et al., 1999; Heller et al., 2009). 
Its extensive functional connectivity with other brain regions including prefrontal 
cortex, hippocampus and amygdala that are also significantly associated with 
depressive disorders implicate a critical role of NAc in MDD pathophysiology 
(Shirayama and Chaki, 2006).  
Volumetric abnormality has been observed in the amygdala of MDD subjects. 
Unmedicated depression patients showed a decrease of amygdala volume compared 
to controls (Hamilton et al., 2008). Depressed female individuals were shown to have 
a smaller amygdala (Hastings et al., 2004) and a hyperactive amygdala has been 
shown in depressed individuals (Drevets et al., 1992; Yang et al., 2010). 
Like other brain regions involved in MDD, a significant volume decrease of the 
thalamus has also been observed in MDD individuals (Nugent et al., 2013). Thalamic 
area hyperactivity was shown to correlate with treatment-resistant depression and 
antidepressant treatment response (Yamamura et al., 2016).  
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1.2. Neurobiology of major depressive disorder 
 
1.2.1. Neurotrophic hypothesis of depression 
Neurotrophic factors are growth factors that are essential for neuronal cell 
proliferation and survival. Based on observations in rodents and depression patients 
low levels of neurotrophic factors have been implicated in the pathobiology of 
depression. They include brain-derived neurotrophic factor (BDNF), nerve growth 
factor (NGF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). Particularly BDNF 
has been extensively studied and associated with depressive disorders. BDNF level 
alterations have also been found in animal models of chronic stress (Murakami et al., 
2005; Dwivedi, 2009). Antidepressants  increase BDNF expression in brain regions 
including the hippocampus and prefrontal cortex (Lee and Kim, 2010). BDNF was 
shown to produce antidepressant-like effects (Shirayama et al., 2002) implying its 
critical role in the pathology and treatment of depressive disorders. 
 
1.2.2. HPA axis hypothesis of depression 
The hypothalamic-pituitary-adrenal (HPA) axis is a network that spans three 
endocrine systems, hypothalamus, pituitary gland and adrenal gland. In response to a 
stressor, neuropeptides including corticotrophin releasing hormone (CRH) and 
arginine vasopressin (AVP) are secreted from the paraventricular nucleus of 
hypothalamus. This causes adrenocorticotrophic hormone (ACTH) release from the 
anterior pituitary, which stimulates adrenal cortex to synthesize and release 
glucocorticoids into the blood stream. Negative feedback control of the HPA axis is 
mediated by glucocorticoid receptor (Figure 2). HPA axis abnormalities have been 
found in depressive disorders. Depression patients have increased cortisol levels in 
body fluids including saliva, plasma and urine (Nemeroff and Vale, 2005). An 
increased volume of the pituitary (MacMaster and Kusumakar, 2004; MacMaster et 
al., 2006) and adrenal gland (Rubin et al., 1995) have been found in patients with 
depressive disorder reflecting stress-induced HPA axis dysregulation. 
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Figure 2. Diagram of the HPA axis (adapted from Sandi, 2004).  
 
 
1.2.3. Monoamine hypothesis of depression 
Drugs and agents that increase monoamine neurotransmitter levels and availability in 
the synaptic cleft have been found to be effective for alleviating depressive symptoms 
(Sangkuhl et al., 2009; Dell'Osso et al., 2011). These observations led to the 
hypothesis that monoamine deficiency may cause depressive symptoms. In this regard, 
depressive disorders have been associated with impaired neurotransmission of 
monoaminergic pathways (D'Aquila et al., 2000; Schmidt and Reith, 2005; Popik et 
al., 2006). Conventional antidepressants including TCAs, SSRIs and MAOIs affect 
monoamine levels including serotonin, norepinephrine and dopamine. Drugs of the 
tricyclic antidepressant (TCA) and selective serotonin reuptake inhibitor (SSRI) type 
inhibit monoamine transporters that regulate extracellular monoamine levels by 
reuptake from the synaptic cleft. The resulting increased neurotransmitter levels 
activate post-synaptic monoaminergic pathways. Monoamine oxidase inhibitor 
(MAOI) increases neurotransmitter levels by inhibiting monoamine oxidase (MAO) 
activity that catalyzes the degradation of monoamine neurotranmitters (Figure 3).   
 
                                                                                                                                              1. Introduction 
5 
 
 
Figure 3. Monoamine neurotransmission in the synapse. 
 
 
1.2.4. Neuroplasticity theory of depression 
Neuroplasticity defines neuronal adaptation which includes structural and functional 
activity changes. Hippocampal synaptic plasticity in the form of long-term 
potentiation (LTP) persistently strengthens electrical signals in the synapse. Calcium, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-Methyl-D-
aspartate (NMDA) receptors, cyclic adenosine monophosphate (cAMP), calcium-
calmodulin-dependent kinase II (CaMKII) and cAMP response element binding 
protein (CREB) are important for the regulation of neuronal plasticity (Pittenger and 
Duman, 2008). Stress was shown to impair LTP in the rodent hippocampus (Kim and 
Diamond, 2002). High levels of glucocorticoid, a stress hormone, suppress 
hippocampal LTP (De Kloet, 2004). In the prefrontal cortex, chronic stress not only 
induces pyramidal cell dendrite atrophy (Cook and Wellman, 2004; Radley et al., 
2004), but also leads to glia and endothelial cell number reduction in animal models 
of stress (Banasr et al., 2007). Depressed individuals show decreased neuroplasticity, 
which was measured by motor cortical excitability in response to transient brain 
stimulation (Ford and Erlinger, 2004; Liukkonen et al., 2006; Elovainio et al., 2009; 
Vogelzangs et al., 2012; Player et al., 2013; Valkanova et al., 2013; Hickman et al., 
2014b). 
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1.3. Biomarkers for major depressive disorder 
Research using animal models and patient specimens has resulted in several 
biomarker candidates for major depressive disorder (MDD).  
C-reactive protein (CRP) is an acute phase protein circulating in blood whose 
concentration rises rapidly in response to physiological changes including infection 
and inflammation (Thompson et al., 1999). Several studies have found that elevated 
CRP level are associated with MDD (Ford and Erlinger, 2004; Liukkonen et al., 2006; 
Elovainio et al., 2009; Howren et al., 2009; Vogelzangs et al., 2012; Valkanova et al., 
2013; Hickman et al., 2014a).  
The HPA axis activity has been suggested as a potential biomarker of MDD. The 
dexamethasone suppression test (DST) has been used to test adrenal gland activity. 
Dexamethasone, a synthetic analogue of cortisol, induces negative feedback control to 
the pituitary gland and suppresses cortisol release from the adrenal gland. Plasma 
cortisol levels in response to dexamethasone injection can be used as a measure for 
HPA axis dysfunction (Targum et al., 1983; Dam et al., 1985; Fountoulakis et al., 
2008). 
BDNF serum levels have been proposed as an MDD biomarker in the clinic (Karege 
et al., 2002; Shimizu et al., 2003; Karege et al., 2005). FK506-binding protein 51 
(FKBP51) is a co-chaperone protein that interacts with glucocorticoid receptor and 
regulates its activity. FKBP51 has been found to be a risk factor for stress-related 
neuropsychiatric disorders including MDD (Lekman et al., 2008; Binder, 2009). 
Several FKBP5 gene polymorphisms have been found to be associated with 
depressive disorders (Appel et al., 2011; Szczepankiewicz et al., 2014). Reduced p11 
mRNA and protein expression in NAc and hippocampus have been reported in 
depressed patients and suicide victims (Svenningsson et al., 2006; Anisman et al., 
2008; Alexander et al., 2010). Despite all the promising research findings none of 
these biomarkers have made it to the clinic to guide diagnosis of depressive disorders. 
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1.4. Antidepressant drugs 
 
1.4.1. First generation of antidepressants 
The first generation of antidepressants was developed in 1950s. Isoniazid and 
iproniazid were used as anti-tuberculosis agents and found to be potent inhibitors of 
MAO and to have psycho-stimulant effects (Healy, 2000). The TCA imipramine was 
subsequently developed by the Swiss psychiatrist Ronald Kuhn. Tricyclics were first 
found to inhibit norepinephrine reuptake and  later also shown to block the serotonin 
transporter (López-Muñoz and Alamo, 2009). Hence TCAs act as serotonin-
norepinephrine reuptake inhibitors (SNRIs) resulting in elevated neurotransmitter 
levels in the synaptic cleft. 
 
1.4.2. Second generation of antidepressants 
MAOIs and TCAs mode of action led to the hypothesis that the drugs’ antidepressant 
activities are related to elevated neurotransmitter levels (Pletscher, 1991). Novel 
SSRIs and selective norepinephrine reuptake inhibitors (SNRIs) were subsequently 
developed and introduced on the market. SSRIs and SNRIs have fewer adverse side 
effects compared to other types of antidepressants. Currently they are used as first line 
medications for the treatment of a wide range of psychiatric disorders.  
 
1.4.3. Antidepressant treatment response  
Approximately 50% of MDD patients do not respond adequately to conventional 
antidepressant treatment (Trivedi et al., 2006; Papakostas, 2009). The patients who 
fail to achieve remission after two or more of antidepressant trials are diagnosed to 
have treatment resistant depression (TRD) (Malhi et al., 2005). The development of 
novel more targeted antidepressant drugs has not been very successful. According to 
several meta-analyses with SSRIs, patients' response rate remains at around 47% 
(Nelson, 1998). 
To overcome this high rate of drug non-response, several clinical strategies have been 
conducted. Augmentation therapy uses a second non-antidepressant agent with 
antidepressant medication. Augmentation treatment with lithium has shown a 
significant increase of response rate (de Montigny et al., 1983; Heninger et al., 1983; 
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Schöpf et al., 1989; Joffe and Schuller, 1993; Stein and Bernadt, 1993). Augmentation 
therapies with thyroid hormone and 5-HT2A receptor antagonists such as trazodone 
have been reported to be more effective than antidepressant monotherapy (Maes et al., 
1996; Joffe, 1997). Various other substances including pindolol, omega-3 fatty acids, 
modafinil, buspirone/bupropion and methylphenidate, testerone, mecamylamine and 
inositol have been used for augmentation therapy (Papakostas, 2009). 
Combination therapy uses multiple antidepressants. The combination of despiramine 
(noradrenergic TCA) with fluoxetine has been shown to be more effective for 
achieving a response in MDD patients (Fava et al., 1994; Nemeroff et al., 1996). 
Using mirtazpine in combination with SSRIs was also found to be effective for TRD 
treatment (Carpenter et al., 1998). The adjunctive effect of mianserin was also found 
superior compared to SSRI monotherapy (Maes et al., 1999; Ferreri et al., 2001).  
Electric and magnetic brain stimulations induce an antidepressant-like effect in TRD 
patients. Deep brain stimulation (DBS) is a surgical method that implants electrodes 
and stimulates certain brain regions (Mayberg et al., 2005; Kennedy et al., 2011). 
Transcranial magnetic stimulation (TMS) applies electro-magnetic fields to stimulate 
a population of nerve cells. Because of its non-invasive and safe nature, TMS is a 
promising therapeutic strategy to treat TRD (George et al., 1995; Pascual-Leone et al., 
1996; Lee et al., 2012). Electroconvulsive therapy is a procedure that applies electric 
current through the brain to induce biochemical and functional activity changes. This 
method has been shown to be effective for the treatment of TRD (Khalid et al., 2008; 
Dierckx et al., 2012; Kellner et al., 2012). 
Novel fast-acting antidepressant-like agents have also been investigated for the 
treatment of TRD. They include scopolamine and ketamine. Scopolamine, an 
antagonist for muscarinic cholinergic receptors has rapid antidepressant-like effects in 
TRD patients (Furey and Drevets, 2006; Drevets et al., 2013; Jaffe et al., 2013). 
Ketamine, an NMDA receptor blocker, also produces a rapid antidepressant effect 
(Murrough et al., 2013; Lally et al., 2014) in TRD patients (Murrough et al., 2013; 
Lally et al., 2014). 
Recent research has delineated potential candidates associated with antidepressant 
treatment resistance. Serotonin transporter (Huezo-Diaz et al., 2009) and serotonin 
autoreceptors (Malagié et al., 2001; Samuels et al., 2015) have been found to be 
critical for the antidepressant response. In addition, alterations and abnormalities of 
the HPA axis have been associated with antidepressant treatment outcome (Binder et 
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al., 2008; Ventura-Juncá et al., 2014). BDNF gene Val66Met polymorphism has been 
also studied with regard to the antidepressant treatment response and was shown to 
result in antidepressant treatment resistance in rodents and humans (Chen et al., 2006; 
Zou et al., 2010a; 2010b; Kocabas et al., 2011). A link between inflammatory 
cytokines and antidepressant response has been documented. Cerebrospinal fluid  IL-
1, IL-6 and TNF-α blood levels in MDD patients were significantly correlated with 
depression severity (Martinez et al., 2012). High cytokine concentrations have been 
found in antidepressant treatment resistant depression patients (Sluzewska et al., 1997; 
Lanquillon et al., 2000; Fitzgerald et al., 2006). 
 
1.5. Personalized medicine strategy 
The high heterogeneity of the antidepressant treatment response requires a tailored 
treatment to improve therapeutic efficacy. Several studies have been conducted to 
identify biological markers that predict and/or evaluate the antidepressant treatment 
response. Genetic polymorphism studies have found polymorphisms in tryptophan 
hydroxylase, serotonin transporter and serotonin 5-HT2 receptor to be statistically 
associated with SSRI treatment outcome (Serretti et al., 2001; Zanardi et al., 2001; 
Arias et al., 2003; Serretti et al., 2006; Ham et al., 2007; Serretti et al., 2007). 
Neuroimaging measurements have identified neurophysiological markers for the 
antidepressant response. Mayberg et al. found that brain region-specific blood glucose 
metabolism changes were observed only in 6-week fluoxetine treatment responder 
MDD patients (Mayberg et al., 2000; 2002). Several studies have reported that a 
decrease of theta cordance from prefrontal electroencephalography during the first 
weeks with either SSRI or SNRI treatment is able to predict symptom improvement 
for the following weeks of continued treatment (Cook et al., 2002; 2005; Bares et al., 
2007). 
Omics data promise to have great potential for the personalized medicine approach in 
psychiatry. Psychiatric patient sub-group stratification based on omics profiling data 
allows a more precise and tailored treatment (Guest et al., 2013; Sethi and Brietzke, 
2015).  
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1.6. Omics analyses 
1.6.1. Quantitative proteomics 
The shotgun proteomics approach has been very successful for the high-throughput 
analysis of complex protein mixtures (Domon and Aebersold, 2010; Meissner and 
Mann, 2014). The method involves enzymatic digestion of proteins into peptides that 
are subjected to tandem mass spectrometry. With the help of stable isotopes 
proteomes can be profiled and compared by quantitative mass spectrometry.  
 
1.6.1.1. Metabolic labeling 
Stable isotopes can be incorporated into proteins during cellular synthesis in vitro and 
in vivo (Figure 4). For the stable isotope labeling of amino acids in cell culture 
(SILAC) method labeled essential amino acids (arginine, lysine and methionine) are 
added to the cell culture medium  (Ong et al., 2002). Due to the mass difference 
between light and heavy isotopes, mass spectrum signals of unlabeled and labeled 
peptides have different mass-to-charge ratio (m/z) values and their intensities can be 
used for quantification. 
Stable isotope labeling in mammals (SILAM) refers to in vivo labeling of the entire 
mammalian proteome with stable isotopes. 
13
C- or 
15
N-containing diets are used for 
partial or full proteome labeling in rodents (Kruger et al., 2008; Zhang et al., 2011b). 
Labeled rodent tissues and organs can serve as reference material to investigate in 
vivo proteome turnover and expression changes (Filiou et al., 2011; Zhang et al., 
2011b; Webhofer et al., 2013). 
 
Figure 4. SILAC and SILAM metabolic labeling methods. 
                                                                                                                                              1. Introduction 
11 
 
1.6.1.2. Post-synthesis labeling 
Chemical probes have been used for post-synthesis labeling of peptides and proteins. 
Whereas metabolic labeling methods require cellular protein synthesis, non-metabolic 
labeling with chemical probes is applied to investigate body fluids. 
Isotope-coded affinity tag (ICAT) consists of three domains, a reactive group for 
labeling amino acids, an isotopically coded linker region and a tag for affinity 
isolation. The ratio of signal intensities between light and heavy ICATs is used for the 
relative quantification of two samples. Four sets of isotope-coded protein label (ICPL) 
probes, ICPL0, ICPL4, ICPL6 and ICPL10, are available for the comparison of four 
different samples. Each probe has a different mass by replacing 
1
H or 
12
C with 
deuterium or 
13
C, respectively.  
Isobaric tags for relative and absolute quantification (iTRAQ) and tandem mass tag 
(TMT) are used for the comparison of multiple biological conditions (Tonack et al., 
2013; Núñez Galindo et al., 2015; Yao et al., 2015). Isobaric tags consist of three 
components, an amine reactive group that allows covalent binding to amino acids, a 
reporter group that includes a differential mass, and balance group between the other 
two components. The different reporter masses from multiple samples can be 
analyzed in one mass spectrometry run. TMT isobaric tags with various combinations 
of 
13
C and 
15
N allow comparison of 10 different samples. 
 
1.6.1.3. Label-free quantitation 
Label-free quantitation is a method based on measuring peptide peak areas, intensities 
or spectral counts. In contrast to protein labeling methods that combine labeled and 
unlabeled samples, during label-free quantitation samples are subjected separately to 
mass spectrometry analysis (Zhu et al., 2010).  
 
1.6.2. Targeted metabolomics 
Metabolomics has been an important method to investigate biological pathway and 
metabolism changes (Sato et al., 2012; Shah et al., 2012; Inoue et al., 2013). It has 
been extensively applied for biomarker research and the identification of affected 
biological pathway (Griffiths et al., 2010; Armitage and Barbas, 2014). 
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Metabolomics analysis has been conducted with several platforms including nuclear 
magnetic resonance, liquid chromatography coupled to mass spectrometry and gas 
chromatography coupled to mass spectrometry. 
Two different strategies can be utilized for metabolomics analysis – untargeted and 
targeted. Untargeted metabolomics assesses all measurable analytes including the 
ones with unknown identity, which requires follow-ups for their identification and 
characterization. Targeted metabolomics captures biochemically characterized small 
molecules. By using internal standards or metabolite signal intensity, targeted 
metabolomics data can be quantitative. Relevant biochemical pathways can be 
enriched by a list of identified metabolites. Quantified metabolite levels also reflect 
pathway activity. 
 
 
1.7. Aim of the thesis 
Using quantitative -omics analyses and in silico data integration this thesis aims at 
identifying biosignatures and molecular pathways relevant for the stratification of 
antidepressant treatment sub-groups and antidepressant efficacy. The study represents 
an attempt to address the high rate of antidepressant non-response, one of the major 
problems in psychiatry, and to bridge the translational gap between preclinical and 
clinical studies.  
The separation of antidepressant responder and non-responder sub-groups is a 
prerequisite for biomarker identification. My –omics analyses were carried out with 
specimens from an animal model that reflects clinical bimodal distribution of patient 
sub-groups, which was established in Prof. Marianne Müllers laboratory during her 
tenure at the Max Planck Institute of Psychiatry. 
Resulting from -omics profiles of the mouse model, protein signatures that are part of 
the identified pathways were further corroborated in mice and MDD patients’ 
peripheral blood mononuclear cells (PBMCs) with the aim of identifying biomarker 
candidates relevant for assessing antidepressant treatment response. 
                                                                                                                             2. Materials and Methods 
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2. Materials and Methods 
 
2.1. Animal housing and husbandry  
The experiments were performed with male DBA/2J mice (Charles River 
Laboratories, Chatillon-sur-Chalaronne, France). All animals were between 8-10 
weeks old and single-housed for at least one week prior to the beginning of the 
experiments. Mice were held under normal light and temperature conditions (12 light: 
12 dark light cycle, lights on at 7 pm, temperature at 23 ± 2°C, and humidity at 55 ± 
5%) with standard bedding and nesting material, in polycarbonate cages (21 x 15 x 14 
cm). Water and Altromin 1324 standard mouse chow (Altromin GmbH, Lage, 
Germany) were provided ad libitum. All procedures were carried out in accordance 
with the European Communities Council Directive 2010/63/EU and approved by the 
committee for the Care and Use of Laboratory animals of the Government of Upper 
Bavaria, Germany. 
 
2.2. Drug administration 
Mice were treated with either vehicle or 5 mg/kg paroxetine pills (Paroxetine 
hydrochloride Carbone Scientific, London, UK) for 28 days twice a day. Animals 
were randomly assigned to the vehicle- or paroxetine-treated groups. Either vehicle or 
paroxetine was voluntarily self-administered via customized palatable pellets (40mg 
PQPellets, Phenoquest AG, Martinsried, Germany). Animals that did not take the pills 
properly were excluded from further analyses. 
 
2.3. Mouse brain and blood collection 
Blood was collected at least one month before commencing paroxetine treatment from 
retro-orbital puncture and after 28 days of paroxetine treatment through cardiac 
puncture or trunk blood. On day 29, the animals were subjected to a forced swim test 
(FST) and sacrificed. Trunk blood and brains of the animals were collected and stored 
at -80°C until further use. Blood was centrifuged to separate plasma and erythrocytes 
(1300g, 10 min, 4°C) before storage. 
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2.4. Behavioral analysis 
 
2.4.1. Forced Swim Test  
The forced swim test was performed to evaluate antidepressant-like activity of 
chronic paroxetine treatment in DBA2/J mice, and to further stratify paroxetine-
treated mouse sub-groups based on behavior profiles. After 28 days of paroxetine pill 
administration, mice were subjected to the forced swim test on day 29. Mice were 
placed into a glass beaker (height 24 cm, diameter 13 cm) filled with water (21 ± 1°C) 
up to a height of 15 cm, so that the animals were unable to reach the ground or escape 
for 6 min testing. After the test, animals were immediately dried and returned to 
home cage. Main parameter of interest is floating time scored by an experienced 
observer blind to treatment.  
 
2.4.2. Female urine sniffing test  
The female urine sniffing test was conducted to assess anhedonia-like behavior of 
animals before and after chronic paroxetine treatment. The test was performed prior to 
commencing paroxetine treatment and 28 days after treatment. Mice were habituated 
to a cotton swab inserted into their home cage for 1 h prior to testing. Mice were 
exposed to a sterile cotton swab dipped into water for 3 min and after a 45 min inter 
trial interval. Then they were exposed to a sterile cotton swab dipped in estrous 
female urine from the same strain. Total sniffing time was recorded.  
 
2.5. Paroxetine measurements 
Mouse whole brains were homogenized in a fivefold volume of phosphate buffered 
saline containing protease inhibitor cocktail tablets (Roche, Penzberg, Germany) 
using a Dispomix Drive (Medic Tools AG, Zug, Switzerland). All samples were 
prepared using Ostro protein precipitation and phospholipid removal plates (Waters, 
Eschborn, Germany). Plasma and brain homogenates were analyzed by liquid 
chromatography-electrospray tandem mass spectrometry (LC-MS/MS) using an 
Agilent 1100 Series (Agilent, Waldbronn, Germany) liquid chromatograph interfaced 
with an Applied Biosystems API 4000 (ABSciex, Darmstadt, Germany) triple 
quadrupole mass spectrometer. Deuterated paroxetine (Paro-D6) was used as internal 
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standard. Five µl samples were loaded and gradient eluted from an Accucore RP-MS 
2.6 µm column (2.1 x 50 mm, Thermo Scientific, Dreieich, Germany) at a flow rate of 
0.3 ml/min and 30°C (eluent A: methanol, 10 mM ammonium formate, 0.1% formic 
acid eluent B: 10 mM ammonium formate, 0.1% formic acid). Gradient: 0-0.5 min 20% 
A, 0.5-2 min 20- 90% A, 1 min held at 90% A, 3-3.5 min 90-20% A and 3.5-8 min 20% 
A. The ion source was operated in positive mode at 500°C and multiple reaction 
monitoring collision-induced dissociation was performed using nitrogen collision gas. 
The collision energy was set to 29 V for paroxetine and 33 V for Paro-D6. The 
transitions monitored during analysis were m/z 330 → 192 for paroxetine and m/z 336 
→ 198 for Paro-D6. 
 
2.6. Omics analyses 
 
2.6.1. Proteomics analysis  
Mouse hippocampus was homogenized in a buffer containing 2M NaCl, 10mM 
HEPES/NaOH, 1mM EDTA and protease inhibitor cocktail tablets (Roche 
Diagnostics, Mannheim, Germany) and phosphatase inhibitors (Sigma, St. Louis, MO, 
USA). Homogenates were sonicated with an ultra-sonicator (Branson, Danbury, CT, 
USA) and centrifuged (16100g, 20 min, 4°C). The protein concentration was 
quantified by Bradford assay. 
Protein extracts were mixed with equal amounts of 
15
N-labeled DBA/2 mouse 
hippocampal protein extract (Sato et al., 2012; Shah et al., 2012; Inoue et al., 2013). 
Fourty µg of 
14
N- 
15
N hippocampal protein mixture was separated in a 10% SDS-
PAGE gel and stained with Coomassie Brilliant Blue R-250 (BioRad, Hercules, CA, 
USA) overnight. After destaining and cutting the gel lane into slices, gel bands were 
further destained 3 times with 25 mM NH4HCO3/50% acetonitrile (Merck, Darmstadt, 
Germany). The gel slices were then reduced with 10 mM dithiothreitol (BioRad, 
Hercules, CA, USA) for 30 min at 56°C and carboxyadminomethylated with 50 mM 
iodoacetamide (Biorad, Hercules, CA, USA) for 30 min at room temperature, 
followed by additional twice of washing with with 25 mM NH4HCO3/50% 
acetonitrile. The gel slices were subjected to tryptic digestion to produce peptides 
(overnight, 37°C). Tryptic peptides were extracted with 2% formic acid/50% 
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acetonitrile (Merck, Darmstadt, Germany) with shaking. The peptides were 
lyophilized and dissolved in 1% formic acid (Merck, Darmstadt, Germany). The 
extracted peptides were analyzed by LC-MS/MS using a nanoflow HPLC-2D system 
(Eksigent, Dublin, California) coupled online to an LTQ-Orbitrap mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany). Proteins were identified by Sequest 
(Thermo Fischer, Scientific, Bremen, Germany) search using a decoy Uniprot mouse 
protein 
14
N and 
15
N database. Peptide search results were filtered and combined with 
the help of Trans-Proteomic Pipeline (TPP). Based on protein group detection data 
from TPP, protein quantitation was carried out using ProRata software (version 1.0). 
 
2.6.2. Metabolomics analysis 
A 30-fold excess (w/v) of 80% cold methanol was added to the hippocampus and 
prefrontal cortex. Brain tissues were homogenized (1200 min
-1
, 2 min, Potter-S 
homogenizer, Sartorius, Göttingen, Germany) on ice and centrifuged (14000g, 10 
min, 4°C). Supernatants were transferred and a 6-fold excess (w/v) of 80% cold 
methanol was added to the pellets. Pellets were sonicated to further extract 
metabolites and combined with the previous supernatants. Combined samples were 
vortexed, centrifuged (14000g, 10 min, 4°C) and lyophilized.  
Mouse plasma metabolites were extracted with a 4-fold excess (v/v) of 100% cold 
methanol. After vortexing for 2 min, samples were incubated on dry ice for 2 h and 
centrifuged (2053 g, 10 min, 4°C). Supernatants were filtered using a 0.22 μm 
ultrafiltration tube (1105g, 2 min, 4°C) and the filtrates were lyophilized. The 
lyophilized metabolites were stored at -80°C until further use. Samples were 
dissolved in 20 μl liquid chromatography-mass spectrometry grade water. Ten 
microliters were injected and analyzed using a 5500 QTRAP triple quadrupole mass 
spectrometer (AB/SCIEX, Framingham, MA, USA) coupled to a Prominence UFLC 
high-performance liquid chromatography system (Shimadzu, Columbia, MD, USA) 
via selected reaction monitoring of a total of 280 endogenous water-soluble 
metabolites for steady-state analyses of samples. Samples were delivered to the mass 
spectrometer via normal phase chromatography using a 4.6-mm i.d × 10 cm Amide 
Xbridge HILIC column (Waters, Milford, MA, USA) at 350 μl min
−1
. Gradients were 
run starting from 85% buffer B (high-performance liquid chromatography grade 
acetonitrile) to 42% B from 0 to 5 min 42% B to 0% B from 5 to 16 min 0% B was 
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held from 16 to 24 min 0% B to 85% B from 24 to 25 min 85% B was held for 7 min 
to re-equilibrate the column. Buffer A comprised 20mM ammonium 
hydroxide/20mM ammonium acetate (pH = 9.0) in 95:5 water:acetonitrile. Some 
metabolites were targeted in both positive and negative ion modes for a total of 291 
selected reaction monitoring transitions using positive/negative polarity switching. 
Electrospray ionization voltage was +4900 V in positive ion mode and − 4500 V in 
negative ion mode. The dwell time was 4ms per selected reaction monitoring 
transition and the total cycle time was 1.89 s. Approximately 9–12 data points were 
acquired per detected metabolite. Peak areas from the total ion current for each 
metabolite-selected reaction monitoring transition were integrated using the 
MultiQuant v2.0 software (AB/SCIEX). Animals from the same cohort were used for 
all metabolomics analyses. Animals from the same cohort were used for all 
metabolomics analyses.  
 
2.7. Molecular techniques 
 
2.7.1. qRT-PCR 
Hippocampal total RNA was isolated with TRIzol reagent (Invitrogen, Karlsruhe, 
Germany) as previously described (Schmidt et al., 2010). RNA levels were quantified 
using NanoPhotometer (IMPLEN, Munich, Germany). One ug of RNA was subjected 
to reverse transcription using Omniscript RT kit according to manufacturer’s protocol 
(Quiagen, Santa Clarita, CA, USA). QuantFast SYBR Green PCR kit (Quiagen, Santa 
Clarita, CA, USA) was used for Quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR). The reaction was performed using LightCycler 480 
(Roche Diagnotics, Penzberg, Germany). The cycling condition used was as follows: 
denaturation step at 95°C for 10min, followed by 45 cycles of amplification step 
(95°C for 10sec, 60°C for 30sec, for each cycle). Each set of primer was used for 
detection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), nNOS, NR1, 
NR2A, NR2B and PSD95 (Eurofins MWG Operon, Ebersberg, Germany) (Table 1). 
Each sample was analyzed in duplicate and normalized with GAPDH level. Relative 
quantitation was performed based on crossing points value (Pfaffl, 2001).  
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Table 1. List of primers used for qRT-PCR analysis. 
 
2.7.2. Immunoprecipitation  
Hippocampal proteins were extracted and immunoprecipitated using Pierce Direct IP 
kit (Thermo Fisher Scientific, Rockford, IL, USA). Mouse hippocampus was 
homogenized with IP lysis/wash buffer containing 2% SDS (Sigma, St. Louis, MO, 
USA), protease inhibitor cocktail tablets (Roche Diagnostics, Mannheim, Germany) 
and phosphatase inhibitors (Sigma, St. Louis, MO, USA). Lowry assay was 
performed to measure protein concentration with DC Protein Assay kit (Bio-Rad 
Laboratories, Munich, Germany). 10ug of Ub antibody (Santa Cruz, Dallas, TX, USA) 
was covalently bound to the resin according to manufacturer’s protocol. 500ug of 
hippocampal lysates were boiled (95°C, 10 min) and diluted with 5 volumes of IP 
lysis/wash buffer containing 2% Triton X-100, protease inhibitor cocktail tablets 
(Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitors (Sigma, St. 
Louis, MO, USA). The lysates were incubated with Ub antibody-coupled resin (4°C, 
overnight). The resin was washed three times with IP lysis/wash buffer and was 
boiled with 1×SDS loading buffer for elution (95°C, 10 min). Immunoprecipitates 
were separated in a 10% SDS-PAGE gel, and Western blot analysis was performed 
with NR1, NR2A and PSD-95 antibodies. Ubiquitinated protein levels were 
normalized by total ubiquitination intensity. 
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2.7.3. Western blot analysis 
Mouse hippocampus, prefrontal cortex and erythrocytes were homogenized with the 
same buffer used for proteomics sample preparation, or RIPA buffer containing 
protease inhibitor cocktail tablets (Roche Diagnostics, Mannheim, Germany) and 
phosphatase inhibitors (Sigma, St. Louis, MO, USA). Patient PBMCs were 
homogenized with RIPA buffer containing protease and phosphatase inhibitors. 
Homogenates were sonicated and centrifuged (16100g, 20 min, 4°C). Bradford assay 
was used to quantify extracted protein concentration. Proteins were separated in 10-15% 
gradient SDS-PAGE gels. Subsequently, they were transferred to a PVDF membrane 
(Millipore, Billerica, MA, USA). After blotting, the membrane was blocked with 5% 
skim milk solution for 1 h at room temperature and incubated with β-actin (1:4000, 
Sigma, St.Louis, MO, USA), aminoimidazole-4-carboxamide ribonucleotide 
transformylase/IMP cyclohydrolase (ATIC) (1:500, Santa Cruz, Dallas, TX, USA),  
Ca
2+
/calmodulin-dependent protein kinase (CaMK) II (1:2000, Abcam, Cambridge, 
UK), carboxy-terminal PDZ ligand of nNOS (CAPON) (1:500, Santa Cruz, Dallas, 
TX, USA), carbamoyl phosphate synthase 2 (CPS2) (1:500, Santa Cruz, Dallas, TX, 
USA), extracellular signal-regulated kinase (ERK) (1:1000, Cell Signaling, Danvers, 
MA, USA), glutamate dehydrogenase 1 (GDH1) (1:1000, Aviva System Biology, San 
Diego, CA, USA), glutamine synthetase (GS) (1:1000, Sigma, St.Louis, MO, USA), 
glycogen synthase kinase-3β (GSK-3β) (1:1000, Cell Signaling, Danvers, MA, USA), 
soluble guanylate cyclase-β1 (sGC-β1) (1:500, Santa Cruz, Dallas, TX, USA), 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) (1:500, Sigma, St. Louis, 
MO, USA), mitochondrial aspartate transaminase (mAST) (1:500, Sigma, St.Louis, 
MO, USA), mitogen-activated protein kinase kinase (MEK) (1:1000, Cell Signaling, 
Danvers, MA, USA), neuronal nitric oxide synthase (nNOS) (1:1000, Cell Signaling, 
Danvers, MA, USA), N-Methyl-D-aspartate (NMDA) receptor subunit (NR) 1 (1:500, 
Santa Cruz, Dallas, TX, USA), NR2A (1:500, Santa Cruz, Dallas, TX, USA), NR2B 
(1:500, Santa Cruz, Dallas, TX, USA), phospho-CaMKII (P- CaMKII) (1:1000, Cell 
Signaling, Danvers, MA, USA), phospho-ERK (P-ERK) (1:1000, Cell Signaling, 
Danvers, MA, USA), phospho-GSK-3β (Ser9) (P-GSK-3β) (1:1000, Cell Signaling, 
Danvers, MA, USA), phospho-MEK (P-MEK) (1:1000, Cell Signaling, Danvers, MA, 
USA), phospho-NR1 (P-NR1) (1:500, Santa Cruz, Dallas, TX, USA),  phospho-
NR2A (P-NR2) (1:500, Santa Cruz, Dallas, TX, USA),  phospho-NR2B (P-NR2B) 
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(1:500, Santa Cruz, Dallas, TX, USA), postsynaptic density protein 95 (PSD-95) 
(1:1000, GeneTex, Irvine, CA, USA), proteasome subunit α type-2 (PMSA2), 
synapsin (1:1000, Cell Signaling, Danvers, MA, USA), synaptic vesicle glycoprotein 
2A (SV2A), synaptojanin 1 (SYNJ1), syntaxin binding protein1 (STXBP1) or 
ubiquitin (Ub) (1:500, Santa Cruz, Dallas, TX, USA) antibody at 4°C overnight. 
PMSA2, SYNJ1, STXBP1 and SV2A antibodies were provided by the Human Protein 
Atlas (HPA) program (Albanova University Center, Royal Institute of Technology, 
Sweden). 
The membranes were washed and then incubated with horseradish peroxidase (HRP) 
conjugated-secondary antibodies. The blots were developed with Luminata
TM
 Forte 
Western HRP Substrate (Millipore, Billerica, MA, USA). Images were acquired by 
ChemiDoc
TM
 MP imaging system (Bio-Rad Laboratories, Munich, Germany). 
Densitometric data analyses were carried out with ImageJ software (National Institute 
of Health, USA). 
 
2.8. Patient samples 
For in vivo and ex vivo studies, two distinct PBMC batches from different individuals 
were chosen. PBMCs obtained from 17 participants of the Munich Antidepressant 
Response Signature (MARS) study were included for assessing protein expression 
levels (Table 2). PBMCs from 32 individuals were subjected to ex vivo cultivation 
and paroxetine treatment (Table 3). Diagnosis was conducted according to DSM-IV 
criteria, and all participants were diagnosed as having MDD. Depression severity was 
evaluated using the 21-item Hamilton Depression Rating Scale (HDRS). Responder 
and non-responder patients were classified based on clinical antidepressant treatment 
response corresponding to minimal 50% reduction in HDRS score between baseline 
(T0) and after 6 weeks of admission (T6). The Munich Antidepressant Response 
Signature (MARS) project was approved by the ethics committee of the Medical 
Faculty at Ludwig Maximilians University of Munich, Germany (submission number 
318/00). Participants included in the study gave oral and written consents after 
receiving a complete description of the study. 
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Table 2. Demographic features of antidepressant treatment responder and non-
responder patients. 
 
 
 
Table 3. Demograhic and clinical characteristics of antidepressant responders 
and non-responders included in ex vivo PBMCs cultivation and paroxetine 
treatment. 
 
2.8.1. Paroxetine treatment of PBMCs  
Blood of patients with MDD was collected between 08:00 and 09:00 h within 5 days 
after admittance. PBMCs were prepared as described previously (Gassen et al., 2014). 
Blood was collected from depression patients via venepuncture, and centrifuged 
(800g, 20 min) to separate PBMCs. Using Biocoll separating solution, PBMCs were 
enriched and washed with ice-cold PBS. PBMCs were plated at 4×10
5
 cells/cm
2
. 
After 6 hours, cells were treated with 120ng/ml paroxetine for 2 days according to the 
consensus guidelines for therapeutic drug monitoring in psychiatry (Lotrich and 
Pollock, 2005; Hiemke et al., 2011). 
 
 
 
                                                                                                                             2. Materials and Methods  
22 
 
2.8.2. Protein level quantitation in cultivated PBMCs 
In ex vivo cultivated PBMCs, ATIC, CPS2, HPRT and β-actin protein levels were 
detected and quantitated with an automated capillary immunoassay system, Simple 
Western
TM
 (ProteinSimple, Santa Clara, CA, USA). PBMCs lysates were prepared 
according to manufacturer’s instruction. Fluorescent master mix was prepared with 
400mM DTT, 5× fluorescent master mix solution and biotinylated protein ladder. 
Protein lysates were incubated with master mix solution and denatured at 95°C for 5 
min. Protein samples, primary and secondary antibodies were loaded on 96 well plate. 
All following steps were fully automated. Protein levels were quantified using 
antibodies for β-actin (1:150, Sigma, St.Louis, MO, USA), ATIC (1:25, Santa Cruz, 
Dallas, TX, USA) and CPS2 (1:50, Santa Cruz, Dallas, TX, USA). Protein 
quantitation data were normalized with β-actin. Quantitative analysis was performed 
using Compass software (ProteinSimple, Santa Clara, CA, USA). 
 
2.9. Statistical Analysis 
Hierarchical clustering analysis (HCA) was performed to separate paroxetine-treated 
sub-groups of mice, using SPSS (SPSS version 21, IBM SPSS Inc., Chicago, IL, 
USA). Statistical analysis of behavioral data (FST and FUST) and covariates were 
performed with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). 
Student t-test, one-way or two-way ANOVA was used to evaluate statistical 
significance between groups. Pearson correlation coefficients (r) with p values were 
used to evaluate correlation between floating time and body weight gain. For the 
identification of significantly altered metabolites, metabolite peak intensities were 
median and auto-scaled normalized. Metabolites with missing values, 30 for the 
hippocampus and 27 for the prefrontal cortex in all replicates, were excluded from 
data analysis. Significant analysis of microarrays (and metabolites) (SAM) method 
was used to identify significantly altered metabolites (q < 0.05, FDR < 0.1). 
Significantly altered metabolites were subjected to pathway enrichment analysis of 
MetaboAnalyst (http://www.metaboanalyst.ca) to identify differentially affected 
pathways between the PLF and PSF groups. Pathways with Holm adjusted p < 0.05 
and FDR < 0.05 were considered significantly affected. To identify sub-pathways 
interacting with a differentially affected pathway between the PLF and PSF groups, 
correlates of each SAM signature were combined and used to enrich relevant 
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metabolic pathways using MetaboAnalyst (Pearson correlation coefficients (r) > 0.7, 
FDR < 0.1). Pathways with Holm adjusted p < 0.05 and FDR < 0.05 were considered 
significant. Proteomics pathway enrichment was performed using DAVID 
bioinformatics resources 6.7 according to a Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database (Huang et al., 2007). Enriched pathways were considered 
significant at Bonferroni adjusted p < 0.05 and FDR < 0.01. Proteins common to 
several pathways were further extracted from the enriched pathways using a Venn 
diagram comparison. Protein interaction network was created using STRING database. 
Western blot data were analyzed with GraphPad Prism 5. Two-tailed t-test was used 
to evaluate the difference between the groups. Data were expressed as the mean ± the 
standard error of the mean (SEM).  Correlations between pathway protein levels and 
FST floating time/HDRS change were assessed using Pearson correlation coefficients 
(r) with p values. Statistical data were considered significant at p < 0.05. D’Agostino 
& Pearson omnibus normality test was used to check normal distribution. 
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3. Results 
 
Figure 5 shows a schematic overview of the workflow. 
 
 
 
Figure 5. A schematic overview of the workflow. 
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3.1. Sub-grouping of paroxetine responder and non-
responder mice 
DBA/2J mice were administered with vehicle or paroxetine pills (2 x 5 mg/kg/day) 
for 28 days. The paroxetine-treated group (PAR) showed significantly reduced FST 
floating time compared to vehicle-treated (VEH) mice (t = 13.90, df = 143, p < 
0.0001) (Figure 6).  
 
 
 
Figure 6. The effect of chronic paroxetine treatment on FST floating time. Male DBA/2J mice 
received paroxetine (5 mg/kg, twice a day, 28 days) and floating time was recorded for 6 min. 
PAR mice displayed significantly shorter floating time compared to vehicle-treated group 
(VEH). n(VEH/PAR)=50/95. Data are expressed as mean ± SEM. **** p < 0.0001 (two-tailed 
t-test). 
 
I was able to separate paroxetine-treated mice into long-time floating (PLF) and short-
time floating (PSF) groups according to their FST floating time using hierarchical 
cluster analysis (HCA) (F = 159.5, df = 144, p < 0.001) (Figure 7). PSF mice floating 
time was significantly lower than for VEH mice (p < 0.001) while no floating time 
difference was observed between PLF and VEH mice. During the female urine 
sniffing test (FUST) PLF and PSF mice did not show differential sniffing time prior 
to paroxetine treatment (F(5,192) = 104.5, p > 0.05) (Figure 8a). A slightly different 
sniffing time became apparent after 28 days of paroxetine treatment (p = 0.052). The 
time for sniffing female urine was longer for PSF mice compared to VEH and PLF 
mice (F(5,192) = 84.24, df = 197, p < 0.0001) (Figure 8b). Two-way ANOVA identified 
no interaction between time points and treatment. 
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Figure 7. Sub-grouping of paroxetine-treated mice. Dendrogram of paroxetine-treated mice. 
Mice treated with paroxetine were separated into PLF and PSF groups using hierarchical 
clustering analysis (HCA). n(VEH/PLF/PSF)=50/9/86. Data are expressed as mean ± SEM. 
***p < 0.001 (one-way ANOVA with Tukey’s test for multiple comparisons). 
 
 
Figure 8. The effect of chronic paroxetine treatment on female urine sniffing test (FUST). The 
effect of chronic paroxetine treatment on female urine sniffing test (FUST). Sniffing time at (a) 
baseline and (b) after 28 days of paroxetine treatment. Chronic paroxetine treatment induced a 
slightly significant difference of sniffing time between paroxetine-treated long- time floating 
(PLF) and paroxetine-treated short-time floating (PSF) groups. n(VEH/PLF/PSF) = 43/22/34. 
*p < 0.05 (two-tailed t-test), ***p < 0.001 (one-way ANOVA with Tukey’s test for multiple 
comparisons).   
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3.2. Covariate analysis 
Covariates that may be relevant for paroxetine treatment response were examined. 
Paroxetine concentrations in whole brain and plasma did not differ between groups (p 
> 0.05) and did not correlate with FST floating time (r = 0.26, p = 0.387) (Figure 9a 
and b). I also analyzed mouse age and body weight gain. A significant age effect on 
FST floating time was not observed (F(4,81) = 2.184, p > 0.05) (Figure 10).  
 
 
Figure 9. Paroxetine levels in (a) whole brain and (b) plasma. PLF and PSF groups did not 
show significant paroxetine level differences, n(PLF/PSF)=5/8. Pearson correlation coefficients 
(r) with P values are indicated in the correlation graphs. 
 
 
Figure 10. The effect of age on FST floating time, n(VEH/PLF/PSF)=50/9/86. *p < 0.05 (one-
way ANOVA with Tukey’s test for multiple comparisons).  
 
Body weight gain did not vary between PLF and PSF mice. Both groups had a 
significantly higher body weight gain after chronic paroxetine treatment compared to 
VEH mice (F(2,42) = 29.51, p < 0.0001). Correlation between body weight gain and 
FST floating time was not significant (VEH: r = - 0.02, p = 0.876 PLF: r = - 0.32, p = 
0.405 PSF: r = - 0.15, p = 0.169) (Figure 11). 
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Figure 11. The effect of body weight gain on FST floating time, n(VEH/PLF/PSF)=50/9/86. 
Data are expressed as the mean ± SEM. *p < 0.05, ***p < 0.001 (one-way ANOVA with 
Tukey’s test for multiple comparisons). Pearson correlation coefficients (r) with P values are 
indicated in the correlation graphs. 
 
3.3. Identification of purine and pyrimidine metabolism 
After clustering paroxetine-treated mice into long-floating and short-floating groups, I 
performed metabolomics and proteomics analyses of the hippocampus. Both -omics 
analyses showed purine/pyrimidine metabolites and proteins with significant 
differences between the two groups (log2|FC| > 0.3, -log10(p value) > 1.3) (Figure 12).  
 
Figure 12. A volcano plot of hippocampal metabolome and proteome. Metabolites and proteins 
with log2|FC| > 0.3 and –log10(p value) > 1.3 were considered significant. Purine/pyrimidine 
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metabolites and metabolism-related proteins were found to be significantly different between 
the sub-groups, n=3-5/group.  
 
In metabolomics analysis, significant analysis of microarrays (and metabolites) (SAM) 
and SAM-driven correlation analysis revealed that chronic paroxetine treatment 
differentially affected the hippocampal metabolome of the PLF and PSF mice (Figure 
13).  
 
 
Figure 13. A heat map with combined profiles of SAM signatures (q < 0.05, FDR < 0.1) and 
their significant correlates (r > 0.7, p < 0.05). Heat map colors denote normalized metabolite 
intensity, n=5/group.  
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Sixteen metabolites were differentially regulated showing significantly higher levels 
in PSF compared to PLF mice (q < 0.05, FDR < 0.1). In addition, I found significant 
correlations with 42 other hippocampal metabolites (r > 0.7, FDR < 0.1) (Figure 14).  
 
 
Figure 14. Hippocampal SAM metabolites (q < 0.05, FDR < 0.1) and their significant correlates 
(r > 0.7, p < 0.05) 
 
In proteomics analysis, I found that purine/pyrimidine metabolism proteins including 
S-adenosyl-L-homocysteine hydrolase (AdoHcyase), S-adenosyl-L-homocysteine 
hydrolase 2 (AdoHcyase 2), guanine deaminase (GDA), inosine triphosphate 
pyrophosphatase (ITPase), purine nucleoside phosphorylase (PNP) and UMP-CMP 
kinase (UMP/CMPK) were differentially expressed between the PLF and PSF groups  
(Figure 15).  
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Figure 15. Identification of purine and pyrimidine metabolism pathway proteins in proteomics 
analysis. 266 and 264 proteins were found to be up- and down-regulated between PLF and PSF 
mice. Purine and pyrimidine metabolisms protein levels were significantly different between the 
PLF and PSF mice (p < 0.05), n=3/group. Data are expressed as the mean ± SEM. **p < 0.01, 
***p < 0.001, ****p < 0.0001 (two-tailed t-test).  
 
The pyrimidine metabolism pathway was enriched with four metabolites from 
hippocampal SAM analysis (carbamoyl phosphate, dihydroorotate, orotate and 
thymidine). Eight correlates of SAM signatures (adenine, adenosine 5-phosphosulfate, 
ADP, dGDP, glutamine, IDP, ppGpp, xanthosine) enriched the purine metabolism 
pathway (Holm adjusted p < 0.05, FDR < 0.05) (Figure 16).  
 
 
Figure 16. Metabolic pathway anlaysis in the hippocampus. Metabolomics analysis identified 
purine and pyrimidine metabolisms as sub-pathway and affected pathway, respectively (Holm 
adjusted p < 0.05, FDR < 0.05).  
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Average levels of purine and pyrimidine metabolites were significantly higher in PSF 
than PLF mice and were strongly correlated with FST floating time (Figures 17a and 
b).  
 
Figure 17. Purine and pyrimidine metabolite average levels and correlation with FST floating 
time. (a) Average level difference of purine and pyrimidine metabolites between PLF and PSF 
group was shown by box plots with whiskers min to max. (b) Average purine and pyrimidine 
pathways metabolite levels were strongly correlated with FST floating time. Data are expressed 
as the mean ± SEM. ****p < 0.0001 (two-tailed t-test). Pearson correlation coefficients (r) with 
p values are indicated under the correlation graphs. 
 
 
Figure 18. Levels of hippocampal metabolites that are part of pyrimidine metabolism pathway 
and correlation with FST floating time. n = 5/group. Bars represent mean ± SEM. **p < 0.01, 
***p < 0.001 vs PLF (two-tailed t-test). Pearson correlation coefficients (r) with p values are 
indicated in the correlation graphs. 
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Purine and pyrimidine metabolite levels were higher in the PSF compared to PLF 
groups and with the exception of adenine and adenosine phosphosulfate showed a 
significant negative-correlation with FST floating time (Figures 18 and 19). 
Metabolomics analysis of the prefrontal cortex did not result in any metabolite and 
pathway differences distinguishing the PLF and PSF groups. 
 
 
 
Figure 19. Levels of hippocampal metabolites that are part of purine metabolism pathway and 
correlation with FST floating time. n = 5/group. Bars represent mean ± SEM. *p < 0.05, **p < 0.01 vs 
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PLF (two-tailed t-test). Pearson correlation coefficients (r) with p values are indicated in the correlation 
graphs. 
 
Figure 20. The effect of chronic paroxetine treatment on ATIC, CPS2 and HPRT protein 
expressions in the mouse hippocampus and prefrontal cortex. (a) Western blot and densitometry 
analyses of the pathway protein levels in the hippocampus and prefrontal cortex. Hippocampal 
ATIC, CPS2 and HPRT proteins showed significant expression level differences between the 
PLF and PSF groups, n=5/group. (b) Correlation of hippocampal CPS2 and HPRT protein 
levels with FST floating time was significant in the hippocampus. ATIC protein level showed 
moderate correlation with FST floating time.  n=15. (c) Correlation of FST floating time with 
the pathway protein levels in the prefrontal cortex. None of the pathway protein showed 
significant correlation with FST floating time. n=15. Protein expression levels were normalized 
with β-actin. Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-
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tailed t-test). Pearson correlation coefficients (r) with p values are indicated in the correlation 
graphs. 
 
Aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase 
(ATIC), carbamoyl phosphate synthase 2 (CPS2) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) protein expression in the hippocampus and 
prefrontal cortex were assessed to validate differentially affected pathways between 
the PLF and PSF groups (Figure 20a). In the hippocampus, ATIC, CPS2 and HPRT 
protein levels showed significant differences between groups. Compared to the PLF 
group the PSF group had significantly reduced ATIC, CPS2 and HPRT protein 
expression levels (ATIC: t = 3.304, df = 8, p < 0.05, CPS2:  t = 1.702, df = 8, p < 
0.001, HPRT: t = 3.488, df = 8, p < 0.01). In the prefrontal cortex protein expression 
showed no difference between the two groups. FST floating time significantly 
correlated with CPS2 and HPRT protein expression levels in the hippocampus, but 
not in the prefrontal cortex. Correlation between FST floating time and ATIC protein 
levels also showed strong tendency in the hippocampus (Figures 20b and c). 
 
3.4. Metabolomics analysis of mouse plasma  
To delineate peripheral metabolome changes related to chronic paroxetine treatment 
response, plasma metabolite levels were investigated in the PLF and PSF groups at 
baseline (T0) and following 28 days of drug treatment (T4). While metabolomic 
profiles between PLF and PSF groups showed no significant differences both at T0 
and T4, the PSF group exhibited profound differences with 43 significant metabolite 
level changes between T0 and T4 and another 71 metabolites that were strongly 
correlated (r > 0.7, FDR < 0.1) (Figure 21a). In the PSF group pyrimidine metabolism 
was enriched with 6 metabolites (carbamoyl phosphate, CMP, dTMP, thymine, UDP, 
UMP) and another 7 metabolites (adenosine, AMP, GMP, guanine, hypoxanthine, 
IMP, uric acid) enriched the purine metabolism pathway (Holm adjusted p < 0.05, 
FDR < 0.05) (Figure 22). The PLF group exhibited smaller metabolome changes 
compared to the PSF group. Only 4 metabolites were significantly altered after 
chronic paroxetine treatment according to SAM with another 32 metabolites highly 
correlated (r > 0.7, FDR < 0.1) (Figure 21b). While SAM signatures revealed no 
significantly affected pathways for the PLF group, glycine, serine and threonine 
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metabolism was enriched for 5 correlates (choline, dimethylglycine, guanidoacetic 
acid, serine and threonine) (Holm adjusted p < 0.05, FDR < 0.05) (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Significant plasma metabolite level changes after chronic paroxetine treatment. Plasma 
SAM metabolites (q < 0.05, FDR < 0.1) and their significant correlates (r > 0.7, p < 0.05) in (a) 
PSF and (b) PLF groups. 
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Figure 22. Chronic paroxetine treatment induced differential metabolome alterations in PSF 
mouse plasma. (a) Heat maps and (b) identified pathways of PSF groups comparing 
metabolome at baseline (T0) and following 28 days of treatment (T4). Purine and pyrimidine 
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metabolisms were the only affected pathways in the PSF group (Holm adjusted p < 0.05, FDR < 
0.05). Heat map colors denote normalized metabolite intensity, n=5/group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. (a) Heat maps and (b) identified pathways of PLF groups comparing metabolome at 
baseline (T0) and following 28 days of treatment (T4). Correlates of SAM signatures identified 
glycine, serine and threonine metabolism as a sub-pathway (Holm adjusted p < 0.05, FDR < 
0.05). Heat map colors denote normalized metabolite intensity, n=5/group. 
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Figure 24. Plamsa metabolite average level changes in the identified pathways. Chronic 
paroxetine treatment induced average level changes of (a) purine and (b) pyrimidine pathways 
metabolites in the PSF group, and (c) glycine/serine/threonine pathway metabolites in PLF 
group between T0 and T4, n=5/group. Metabolite levels are expressed with Box plots with 
whiskers min to max. ****p < 0.0001 (two-tailed paired t-test). 
 
Plasma metabolite levels of identified pathways were significantly altered after mice 
had been treated chronically with paroxetine. Purine and pyrimidine metabolism 
pathway average levels were significantly upregylated by chronic paroxetine 
treatment in PSF mouse plasma (Figures 24a and b). In PLF mouse plasma, glycine, 
serine and threonine metabolism pathway was significantly downregulated by chronic 
paroxetine treatment (Figure 24c). Significant purine and pyrimidine metabolite level 
changes between T0 and T4 were observed only in the PSF mice. In PSF mice, 
chronic paroxetine treatment induced significant upregulation of pyrimidine pathway 
metabolites (carbamoyl phosphate, CMP, dTMP, thymine, UDP, UMP, Figure 25) 
and purine pathway metabolites (adenosine, AMP, GMP, guanine, hypoxanthine, IMP, 
uric acid, Figure 26). Glycine, serine and threonine pathway metabolite level changes 
occurred both in PLF and PSF mice (Figure 27). Plasma levels of 2,3-
dihydroxzbenzoic acid, aminoadipic acid, choline, pantothenate, taurine, threonine 
and uracil were found to be regulated to a similar extent in both PLF and PSF groups 
(Figure 28). 
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Figure 25. Plasma pyrimidine pathway metabolite levels. The metabolite levels in the PSF 
group were elevated by chronic paroxetine treatment. The PLF and PSF groups exhibited 
similar metabolite levels both at T0 and T4. n = 5/group. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 (two-tailed paired t-test). 
 
 
Figure 26. Plasma purine pathway metabolite levels. The metabolite levels in the PSF group 
were elevated by chronic paroxetine treatment. The PLF and PSF groups exhibited similar 
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metabolite levels both at T0 and T4. n = 5/group. *p < 0.05, **p < 0.01, ***p < 0.001 (two-
tailed paired t-test). 
 
 
 
Figure 27. Plasma glycine, serine and threonine metabolism pathway metabolite levels. Glycine, 
serine and threonine metabolite levels in PLF and PSF mice. Both PLF and PSF mice showed 
that glycine, serine and threonine metabolite levels were significantly down-regulated by 
chronic paroxetine treatment. n = 5/group. *p < 0.05, **p < 0.01 (two-tailed paired t-test). 
 
 
 
Figure 28. Common plasma SAM signatures between the PLF and PSF groups. q value < 0.05 
in either PLF or PSF groups, FDR < 0.1. 
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For validation of peripheral pathways identified in plasma, erythrocytes were chosen 
as source. Interestingly, erythrocytic ATIC, CPS2 and HPRT proteins were 
differentially expressed between the PLF and PSF groups. Erythrocytic ATIC and 
CPS2 protein expression in the PSF mice was 1.2-fold and 2.4-fold higher than in the 
PLF mice, respectively (ATIC: t = 4.991, df = 8, p < 0.01, CPS2: t = 4.484, df = 8, p 
< 0.01). HPRT protein levels were 1.7-fold higher in the PSF compared to the PLF 
group (t = 3.145, df = 8, p < 0.05) (Figure 29a). Furthermore, CPS2 and HPRT 
protein levels were significantly correlated to FST floating time. Correlation between 
FST floating time and ATIC protein levels showed tendency (Figure 29b). 
 
 
Figure 29. The effect of chronic paroxetine treatment on ATIC, CPS2 and HPRT protein 
expressions in the mouse erythrocytes. (a) Western blot and densitometry analyses of CPS2 and 
HPRT protein levels in the erythrocytes. Erythrocytic ATIC, CPS2 and HPRT proteins showed 
significant expression level differences between the PLF and PSF groups, n=5/group. (b) 
Correlation of the pathway protein levels with FST floating time. CPS2 and HPRT protein 
levels with FST floating time was significant. ATIC protein moderately correlated with FST 
floating time, n=15. Protein expression levels were normalized with β-actin. Data are expressed 
as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-tailed t-test). Pearson correlation 
coefficients (r) with p values are indicated in the correlation graphs. 
                                                                                                                                                      3. Results 
43 
 
3.5. Analysis of peripheral patient specimens  
Next, I sought to corroborate my findings on pyrimidine and purine metabolism in 
patients chronically treated with antidepressants. For this purpose I carried out 
experiments with PBMCs isolated from patients. 
First, the same pyrimidine and purine pathway proteins analyzed in mice, ATIC, 
CPS2 and HRPT, were assessed in PBMCs obtained from antidepressant responder 
and non-responder patients of the MARS study. In PBMCs collected after 4-6 weeks 
of antidepressant treatment, ATIC and CPS2 protein levels were significantly 
correlated with clinical antidepressant treatment response (ATIC: r = 0.52, p = 0.034 
CPS2: r = - 0.69, p = 0.002 HPRT: r = - 0.23, p = 0.365) (Figure 30a). 
To further investigate pharmacological effects of paroxetine I also performed ex vivo 
experiments with patients’ PBMCs. Cells collected from patients upon admittance 
were cultivated and treated with paroxetine for 2 days. As had been the case for the in 
vivo PBMCs analysis, ATIC and CPS2 protein levels also significantly correlated 
with patients’ clinical antidepressant response when their cultured PBMCs were 
treated with paroxetine (ATIC: r = - 0.37, p = 0.048 CPS2: r = - 0.39, p = 0.029 
HPRT: r = 0.05, p = 0.789) (Figure 30b).  
 
 
Figure 30. Correlation of ATIC, CPS2 and HPRT protein levels with clinical antidepressant 
treatment response. (a) Depression patients’ PBMCs collected after 4-6 weeks of antidepressant 
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treatment were analyzed for ATIC, CPS2 and HPRT protein expression. ATIC and CPS2 
protein levels significantly correlated with clinical antidepressant response, n=17. (b) PBMCs 
from inpatients with depression were collected at admission. Cells were ex vivo cultivated and 
treated with paroxetine for 2 days. After treatment, ATIC and CPS2 protein levels significantly 
correlated with clinical antidepressant response, n=32. Pearson correlation coefficients (r) with 
p values are indicated in the correlation graphs. 
 
3.6. Identification of glutamatergic and ubiquitin proteasome 
system (UPS) pathways 
Mice were treated with paroxetine (5 mg/kg, twice a day) for 28 days. Three animal 
sub-groups, paroxetine-treated long floating (PLF), paroxetine-treated intermediate 
floating (PIF) and paroxetine-treated short floating (PSF) groups were identified 
according to FST floating time (F(3,141) = 132.1, p < 0.0001) (Figure 31).  
 
Figure 31. Sub-grouping of mice treated with paroxetine. Paroxetine-treated mice were 
categorized into PLF, PIF and PSF groups based on FST floating time, 
n(VEH/PLF/PIF/PSF)=50/9/14/72. Data are expressed as the mean ± SEM. ***p < 0.001 (two-
tailed t-test). 
##
p < 0.01 vs. PLF, 
###
p < 0.001 vs. PLF and PIF (one-way ANOVA with Tukey’s 
test). 
To investigate the systemic effect of chronic paroxetine treatment on hippocampal 
molecular pathways, proteomic analyses were performed of the two extreme groups 
(PLF and PSF groups), which resulted in significant protein expression differences. 
Significantly affected pathways related to Amyotrophic lateral sclerosis (ALS), 
Alzheimer’s disease, Huntington’s disease and long-term potentiation commonly 
enriched NR1, NR2A and NR2B proteins. Based on the common protein signatures, 
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glutamate receptors, glutamate metabolism and transport, and synapse and vesicle 
trafficking pathways were also altered (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Proteomics profiles and enriched pathways between the PLF and PSF groups. The 
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common protein signatures among pathways were obtained using Venn diagram analysis and 
further subjected to protein interaction network analysis. In the heatmap, colors denote log2 ratio. 
In the interaction pathway map, colors denote fold difference between the two groups. Proteins 
with |log2FC| > 0.3 and adjusted p value < 0.05 were considered significant, n=5/group. 
Hippocampal metabolite profiling data showed altered levels of relevant NMDA 
receptor modulators and metabolites that are part of the glutamate metabolism 
pathway (Figure 33). All metabolites were at significantly higher levels in PSF 
compared to PLF mice (Figure 34).  
 
Figure 33. A volcano plot comparing PLF and PSF metabolomes. Metabolites with |log2FC| > 
0.3 and –log10(p value) > 1.3 were considered significant, n=5/group. 
 
Figure 34. Glutamate-related metabolite differences between PLF and PSF mice, n=5/group. 
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Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
(two-tailed t-test). 
Altered levels of citrulline whose conversion from arginine is catalyzed by nNOS 
protein were detected as well (Figure 35).  Integration of proteomic and metabolomic 
data sets identified systemic metabolite-protein network differences between the PLF 
and PSF groups (Figure 36). 
 
Figure 35. Arginine and citrulline levels in PLF and PSF mice, n=5/group. Data are expressed 
as the mean ± SEM. **p < 0.01 (two-tailed t-test). 
 
Figure 36. Affected protein-metabolite network following chronic paroxetine treatment. 
Upward-pointing red arrow indicates higher biosignature level in PSF compared to PLF mice. 
Downward-pointing blue arrow indicates lower biosignature level in PSF compared to PLF 
mice. 
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3.7. Validation of glutamatergic and UPS pathways 
Hippocampal NRs and their phosphorylation levels were compared between PLF and 
PSF mice. Except for P-NR1/NR1 and P-NR2B/NR2B ratios, all NRs and P-NRs 
levels were significantly different between the two groups (Figure 37). In addition, 
NR levels were significantly correlated with FST floating time (Figure 38). 
 
Figure 37. NR protein level differences between the sub-groups, n=5/group. Data are expressed 
as the mean ± SEM. *p < 0.05, ***p < 0.001 vs. PLF (two-tailed t-test). 
 
 
 
Figure 38. Correlation of NR protein levels with FST floating time, n=15. Pearson correlation 
coefficients (r) with p values are indicated in the correlation graphs.  
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Hippocampal NMDA receptor signaling proteins and their phosphorylation status 
were also investigated between PLF and PSF groups. Especially, P-ERK, CaMK2 and 
GSK3β levels were significantly different between the two groups (Figure 39) and 
correlated with FST floating time (Figure 40). 
 
Figure 39. NMDA receptor signaling protein level differences between the sub-groups, 
n=5/group. Data are expressed as the mean ± SEM. *p < 0.05, ***p < 0.001 vs. PLF (two-tailed 
t-test). 
 
 
 
Figure 40. Correlation of NMDA receptor signaling protein levels with FST floating time, 
n=15. Pearson correlation coefficients (r) with p values are indicated in the correlation graphs. 
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Nitric oxide (NO) production-related proteins were also significantly different 
between PLF and PSF mice (Figure 41). PSD-95, nNOS and CAPON protein levels 
showed significant correlation with FST floating time (Figure 42). 
 
 
Figure 41. Differential effect of chronic paroxetine treatment on PSD-95/nNOS complex. PSD-
95, nNOS, CAPON and sGC-β1 protein level differences between PLF and PSF mice, 
n=5/group. Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01 vs. PLF (two-tailed t-
test).  
 
 
 
 
Figure 42. Correlation of PSD-95/nNOS complex with FST floating time. PSD-95, nNOS, 
CAPON and sGC-β1 protein levels with FST floating time, n=15. Pearson correlation 
coefficients (r) with p values are indicated in the correlation graphs. 
 
Glutamate metabolism-related protein levels between PLF and PSF mice were further 
investigated in the hippocampus. Particularly GDH1 showed significant level 
differences between the two groups and correlated with FST floating time (Figures 43 
and 44). 
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Figure 43. Glutamate metabolism protein level differences between PLF and PSF mice, 
n=5/group. Data are expressed as the mean ± SEM. **p < 0.01 vs. PLF (two-tailed t-test). 
 
 
Figure 44. Correlation of glutamate metabolism protein levels of FST floating time, n=15. 
Pearson correlation coefficients (r) with p values are indicated in the correlation graphs. 
 
Synapse and vesicle trafficking-associated protein level differences were also 
assessed. Only SYNJ1 protein was found to be significantly different between the 
groups, and correlated with FST floating time (Figures 45 and 46). 
 
 
Figure 45. Synapse and vesicle trafficking-associated protein level differences between PLF 
and PSF mice, n=5/group. Data are expressed as the mean ± SEM. ***p < 0.001 vs. PLF (two-
tailed t-test). 
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Figure 46. Correlation of Synapse and vesicle trafficking-associated protein levels with FST 
floating time, n=15. Pearson correlation coefficients (r) with p values are indicated in the 
correlation graphs. 
 
Since I did not see any NRs, PSD-95 and nNOS transcript level differences between 
PLF and PSF groups (Figure 47) I next examined the possible involvement of the 
UPS protein degradation pathway in the observed protein expression differences. 
Whereas no ubiquitinated NR1, NR2A and PSD-95 differences were detected (Figure 
48), PSF mice showed greater PM2A and ubiquitination levels compared to PLF mice 
(Figure 49), which correlated with FST floating time (Figure 50). 
 
 
Figure 47. qRT-PCR data of NRs, PSD95 and nNOS. No transcription differences were found 
between PLF and PSF groups, n=6/group. Data are expressed as the mean ± SEM. 
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Figure 48. Ubiquitinated NR1, NR2A and PSD-95 protein level differences between PLF and 
PSF groups. No differences were found between PLF and PSF groups, n=3/group. Data are 
expressed as the mean ± SEM. 
 
 
Figure 49. PM2A and ubiquitination level differences between PLF and PSF mice, n=5/group. 
 Data are expressed as the mean ± SEM. *p < 0.05 vs. PLF (two-tailed t-test). 
 
 
 
 
Figure 50. Correlation of PM2A and ubiquitination levels with FST floating time, n=15. 
Pearson correlation coefficients (r) with p values are indicated in the correlation graphs. 
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3.8. Candidate biomarker validation in human PBMCs from 
MDD patients 
To investigate the relevance of the identified biosignatures, sGC- β1, PM2A and 
ubiquitination levels were analyzed in MDD patients’ PBMCs (Figures 51 and 52). 
All three proteins were differentially expressed between the antidepressant responder 
and non-responder patient groups, especially 6 weeks after admission (T6) (Figure 
52a). Whereas sGC-β1 protein levels were significantly reduced in both groups at T6, 
PM2A protein levels were significantly reduced only in responder patients’ PBMCs at 
T6. Ubiquitination levels were not altered by chronic antidepressant treatment in 
either group. However, they were lower in responder compared to non-responder 
patients. All three protein levels significantly correlated with clinical antidepressant 
response at T6 (Figure 52b). Only PM2A protein level changes between baseline (T0) 
and T6 samples significantly correlated with the clinical antidepressant treatment 
response (Figure 52c). 
 
 
 
Figure 51. Western blot anlaysis in MDD patient’s PBMCs. 
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Figure 52. sGC-β1, PM2A and ubiquitination levels in human PBMCs from antidepressant 
responder and non-responder patients. (a) sGC-β1, PM2A and ubiquitination level differences 
between antidepressant non-responder (NR) and responder patients (R) at baseline (T0) and 
after 6-weeks treatment (T6), n=17. (b) Correlation of protein levels at T6 with clinical 
antidepressant treatment response, n=17. (c) Correlation of protein level changes (between T0 
and T6) with clinical antidepressant treatment response, n=17. *p < 0.05, **p < 0.01 vs. NR 
(two-tailed t-test). 
##
p < 0.01, 
###
p < 0.001, 
####
p < 0.0001 vs. T0 (two-tailed paired t-test). Data 
are expressed as the mean ± SEM. Pearson correlation coefficients (r) with p values are 
indicated in the correlation graphs. 
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4. Discussion 
 
4.1. Purine and pyrimidine metabolism pathway 
In my thesis project I have attempted to integrate quantitative proteomics and 
metabolomics data to improve our understanding of biological pathway changes 
relevant for the antidepressant treatment response. Integrated -omics data coupled 
with in silico analysis has delineated several molecular pathways and biomarker 
candidates involved in the differential antidepressant treatment response in mice, 
which were further validated in human MDD patients’ PBMCs.  
Using an inbred mouse strain I was able to stratify paroxetine response sub-groups 
based on animals’ behavioral phenotype. For the unbiased separation of paroxetine 
responder and non-responder mice, I carried out HCA based on FST floating time. 
The HCA has been a method to build and split different hierarchies of clusters. It has 
been applied to identify sub-groups of cells and animals based on marker protein 
expression or behavioral parameters (Droy-Dupré et al., 2015; Muehlmann et al., 
2015). 
The FST is a behavioral test commonly used to evaluate antidepressant-like effects in 
mice (Webhofer et al., 2011; Doucet et al., 2013; Kaster et al., 2013; Weckmann et al., 
2014). I submit that paroxetine-treated mice that exhibit no FST floating time 
difference compared with vehicle-treated mice are drug non-responders. My results 
indicate that 15-40% of the mice are antidepressant non-responders, similar to what is 
observed for MDD patients. 
To further characterize the PLF and PSF sub-groups I also assessed female urine 
sniffing time, a behavioral parameter pertinent to evaluate SSRI treatment effect in 
mice (Malkesman et al., 2010; Wagner et al., 2012). While the PLF and PSF groups 
did not show any difference of female urine sniffing time prior to being treated with 
paroxetine, chronic paroxetine treatment induced a differential behavioral effect 
between the groups. This finding indicates that the different behavior between mice is 
not inherent, but is the result of chronic paroxetine treatment. 
Stratification of sub-groups and tailored treatment has been suggested to result in a 
more favorable outcome and increased treatment efficiency (O'Donnell, 2013; 
Landeck et al., 2016). Sub-group stratification of patients with multifactorial diseases 
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like psychiatric and neurodegenerative disorders need to be assessed for molecular 
and phenotypic signatures. In the current study I only took FST floating time into 
account for the stratification to simplify data processing and interpretation. Including 
other behavioral parameters such as FST swimming and struggling time may add 
further information with regard to the heterogeneous individual response to chronic 
antidepressant treatment. Associated physiological signatures can also be used 
towards this goal. ACTH, corticosterone, CRH and other biomolecules associated 
with psychiatric disorders and treatment, as well as phenotypic markers including 
cognitive function, specific brain region activity and body mass index (BMI) would 
qualify in this regard. Integration of other biological dimensions such as the 
microbiome, lipidome and glycome can also be informative to enhance the systemic 
understanding of depressive disorders and determine sub-groups more precisely. 
To examine the relevance of covariates, drug levels, age and body weight gain were 
assessed. Paroxetine concentrations in whole brain and plasma were analyzed to 
check for a possible association of drug levels with antidepressant-like activity. 
Previous studies have reported a significant relationship between plasma levels and 
therapeutic response towards paroxetine (Yoshimura and Nakano, 2009). An 
association of genetic variants of CYP2D6 and ABCB1, which are involved in drug 
metabolism and permeability, with hetereogenous paroxetine treatment response has 
been suggested previously (Gex-Fabry et al., 2008; Preskorn, 2014). In my study I did 
not find any paroxetine concentration differences between PLF and PSF mice in 
either whole brain or plasma and drug levels did not correlate with FST floating time. 
This suggests that paroxetine levels in whole brain and plasma are irrelevant for the 
observed differential drug treatment response in our long-term treatment setting. I 
also considered animal age and its relationship with paroxetine response. Age-
dependent outcome of SSRI treatment has been assessed with regard to adverse 
effects of drug treatment by comparing antidepressant-induced behavioral response of 
juvenile or adolescent and adult rodents (Olivier et al., 2011; Mitchell et al., 2013). In 
the current study all mice reached adulthood prior to being subjected to experiments 
(> 8 weeks). Although significant FST floating time differences were observed for 
mice between 18 and 20 weeks of age, no general age effect on FST floating time was 
detected. The relationship between body weight gain and chronic paroxetine treatment 
response was also investigated. Chronic paroxetine treatment induced a significant 
                                                                                                                                                4. Discussion 
58 
 
increase of body weight. However, body weight gain and drug treatment response for 
each group did not correlate significantly. 
My integrated metabolomics and proteomics data showed a differential effect of 
chronic paroxetine treatment on mouse hippocampal purine and pyrimidine 
metabolism. Purine and pyrimidine metabolites and their receptors have previously 
been shown to be associated with various neuropsychiatric disorders. The anti-
purinergic drug suramin was found to reverse autism-like behaviors and metabolism 
in mice (Naviaux et al., 2014). Polymorphisms of the P2RX7 gene, which encodes a 
purinergic ion channel, have been associated with the development of MDD (Lucae et 
al., 2006). In addition, low brain purine levels were found in female depressed 
patients responding to treatment with the SSRI fluoxetine (Renshaw et al., 2001). 
Pyrimidines such as cytidine and uridine have been shown to have antidepressant-like 
activities in mice (Carlezon et al., 2002; 2005). 
Hippocampal metabolome profiling also implicated other metabolites with elevated 
levels in PSF mice that have antidepressant-like activity. Folate has been shown to 
have an antidepressant-like effect in mice (Brocardo et al., 2008) and low folate levels 
were found to be associated with MDD (Gilbody et al., 2007). L-Methylfolate, the 
active metabolite of folate is used for patients with MDD who partially respond or do 
not respond to SSRIs (Papakostas et al., 2012). Myo-inositol has been identified as a 
potential biomarker of SSRI treatment response and innate anxiety disorder (Zhang et 
al., 2011a; Webhofer et al., 2013; Zhao et al., 2015) and has been shown to have 
anxiolytic and antidepressant-like effects in both animals and humans (Wurglics and 
Schubert-Zsilavecz, 2006; Herrera-Ruiz et al., 2011) Flavones are also known to have 
an antidepressant-like effect (Wurglics and Schubert-Zsilavecz, 2006; Herrera-Ruiz et 
al., 2011). The elevated levels of folate, myo-inositol and flavones that I found in the 
hippocampus of PSF mice might be of relevance for the favorable paroxetine 
response. 
I also compared the plasma metabolome of the two mouse sub-groups, PLF and PSF, 
at baseline and after 28 days of treatment (T0 and T4) with the aim of identifying 
differentially affected pathways and potential biomarker candidates in the periphery. 
Plasma metabolome changes over time resulted in group-specific profiles. Major 
metabolite level alterations and elevation of purine and pyrimidine metabolites were 
observed in the PSF group. In contrast, the plasma metabolome was minimally 
affected by chronic paroxetine treatment in the PLF group. Despite the fact that the 
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glycine, serine and threonine metabolism pathway was specifically enriched as a sub-
pathway of PLF group, significant metabolite level changes were observed in both 
sub-groups. I also found plasma metabolite biosignatures commonly regulated 
between the PLF and PSF groups. In particular, levels of choline and threonine that 
are part of the glycine, serine and threonine metabolism pathway were significantly 
changed both in the PLF and PSF groups after chronic paroxetine treatment. 
Metabolites of glycine, serine and threonine metabolism may thus constitute 
confounding biosignatures. 
In contrast to hippocampal purine/pyrimidine metabolites, plasma metabolite level 
changes were not correlated with FST floating time. Small plasma metabolite level 
differences between the PLF and PSF groups might be responsible for non-significant 
correlation. Despite non-significant correlation between plasma metabolite level 
changes and chronic paroxetine treatment response, group-specific analysis showed 
PSF-group specific pathway enrichment and significant metabolite changes. 
Based on my integrated -omics data that implicate purine and pyrimidine metabolism 
pathways to be involved in paroxetine response I next wanted to corroborate these 
findings through the analysis of proteins that are part of these pathways. Based on the 
observed differences of carbamoyl phosphate and IMP levels between the PLF and 
PSF groups, ATIC, CPS2 and HPRT protein levels were analyzed. CPS2 catalyzes 
early steps of carbamoyl phosphate synthesis in the pyrimidine biosynthesis pathway. 
ATIC and HPRT play a central role in synthesis and conversion of inosine 
monophosphate (IMP), the end product of the purine biosynthesis pathway. For 
pathway validation I chose hippocampus, prefrontal cortex and erythrocytes and 
compared ATIC, CPS2 and HPRT protein levels between the PLF and PSF groups. 
Western blot analyses revealed that hippocampal and erythrocytic ATIC, CPS2 and 
HPRT proteins were differentially expressed between the two groups while prefrontal 
cortex protein expression showed no difference. Hippocampal and erythrocytic ATIC, 
CPS2 and HPRT protein levels were also highly correlated with FST floating time 
while no significant correlation was observed in the prefrontal cortex. This indicates 
that different purine and pyrimidine metabolism pathway activities between PLF and 
PSF groups might be specific for the hippocampus.  
Interestingly, I observed an inverse relationship between hippocampal and 
erythrocytic protein expression for the three proteins. Inconsistent biosignature 
expression patterns in brain and peripheral tissues have been found in other cases 
                                                                                                                                                4. Discussion 
60 
 
related to psychiatric disorders. Brain and blood BDNF levels were inversely 
correlated in a genetic rat model of depression (Elfving et al., 2010). Brain and white 
blood cell p11 protein levels also showed an inverse relationship (Svenningsson et al., 
2014). Inverse myo-inositol levels between hippocampus and plasma were also 
reported previously in mice chronically treated with paroxetine (Webhofer et al., 
2013). In the current study we found that carbamoyl phosphate and IMP levels have 
an inverse correlation between hippocampus and plasma. This might be caused by the 
observed inverse relationship of ATIC, CPS2 and HPRT enzyme expression levels 
between hippocampus and erythrocytes (Figure 53). 
 
 
 
Figure 53. Correlation between hippocampus and plasma metabolite levels. Carbamoyl 
phosphate and IMP metabolite levels showed inverse relationships between hippocampus and 
plasma. Pearson correlation coefficients (r) with P values are indicated in the correlation graphs.  
 
Lower expression of hippocampal ATIC, CPS2 and HPRT in the PSF group might be 
caused by negative feedback regulation in response to elevated pathway metabolite 
levels. Higher erythrocytic protein levels in the PSF mice might reflect PSF group-
specific activation of purine and pyrimidine metabolisms. 
To address the question whether the pathways for antidepressant response identified 
in the mouse are also relevant for patients’ response, PBMCs from antidepressant 
responder and non-responder patients were analyzed for ATIC, CPS2 and HPRT 
protein expressions. PBMCs collected after 4-6 weeks of antidepressant treatment 
showed significant correlation between ATIC and CPS2 protein expression levels and 
HDRS score change between baseline and following chronic antidepressant treatment. 
Whereas PBMCs ATIC protein expression showed a similar pattern as the one 
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observed in mouse erythrocytes, PBMCs CPS2 protein expression resembled that of 
mouse hippocampus.  
In ex vivo experiments, PBMCs ATIC protein levels were negatively correlated with 
clinical antidepressant response. The observed discrepancy between in vivo and ex 
vivo PBMCs ATIC protein expression could be due to different treatment conditions 
(chronic vs. subchronic) and exposure to multiple types of drugs. PBMCs’ CPS2 
protein expression consistently showed negative correlation with mouse hippocampal 
protein expression both in in vivo and ex vivo. ATIC and CPS2 proteins may thus 
represent candidate biomarkers to determine clinical antidepressant treatment 
response. For HPRT protein, I failed to determine a significant correlation between 
clinical antidepressant response and PBMCs protein levels both in vivo and ex vivo.  
Previously obtained data by Webhofer et al. revealed altered energy metabolism upon 
chronic paroxetine treatment in DBA/2OlaHsd mice when compared to vehicle-
treated control mice (Webhofer et al., 2011; 2013). The previous and current studies 
are not directly comparable since the studies were performed under different 
conditions (groups, dosage and route of paroxetine administration, mouse strain). In 
the current study, energy metabolism-related pathways including glycolysis, Krebs 
cycle and glycogen metabolism that came up in the previous study were not enriched 
when PLF and PSF groups were compared. The current -omics analyses were 
performed to compare PLF and PSF mouse groups and identified purine and 
pyrimidine metabolisms as the main distinguishing pathways. However, based on 
ATP/ADP and NAD
+
/NADH ratios found in the current study I can not exclude that 
energy metabolism might also distinguish the PLF and PSF groups (Figure 54). 
 
Figure 54. Energy-related metabolite ratios in the hippocampus. ATP/ADP and NAD+/NADH 
ratios in the hippocampus in the PLF and PSF group (n = 5/group). Bars represent mean ± SEM. 
*p < 0.05 (two-tailed t-test).  
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Hippocampal neurogenesis is known to be caused by the action of antidepressants 
(Malberg et al., 2000, Santarelli et al., 2003, Gundersen et al., 2013). Since purine and 
pyrimidine metabolites are critical for cell proliferation, increased purine/pyrimidine 
metabolism activity in PSF mice may also result in neurogenesis in these animals. 
Based on evidence from the literature microRNAs (miRNAs) may be also relevant for 
the distinct regulation of purine/pyrimidine metabolisms in the PLF and PSF mouse 
groups. Feng et al have shown that miR-1 and miR-133a-3p regulate purine and 
pyrimidine metabolic pathways (Feng et al., 2015) and the purine metabolism gene 
GART is regulated by 16 miRNAs (Li et al., 2014). Since SSRIs impact miRNA 
levels (Hansen and Obrietan, 2013) this may explain the observed differences in the 
purine and pyrimidine metabolisms upon chronic paroxetine treatment. 
Based on these data a pharmacological study with an inhibitor of the folate pathway 
that also regulates purine and pyrimidine metabolism could shed light on the 
functional relevance of the pathways in chronic antidepressant treatment response. 
The current study used wild-type stress naïve DBA/2J mice to investigate the 
pharmacological heterogeneity of the antidepressant response. Wild-type stress naïve 
rodents have been used previously to evaluate antidepressant-like effects (Guzzetti et 
al., 2008; Gurbuz Ozgur et al., 2015; Taguchi et al., 2016). An extension of our 
studies using an animal model with a depression-like phenotype would further 
validate the identified pathways affected by the antidepressant treatment response and 
add relevant information for the antidepressant treatment of patients. 
 
4.2. Glutamatergic pathway 
My results also suggest that proteins and metabolites associated with the 
glutamatergic pathway are affected by chronic antidepressant treatment which became 
apparent with the categorization of a paroxetine-treated intermediate floating (PIF) 
group. 
The glutamatergic pathway has previously been associated with MDD pathobiology 
and antidepressant response. In depressed patients, significantly elevated serum, 
plasma and cerebrospinal fluid glutamate levels were found (Kim et al., 1982; 
Altamura et al., 1993; Mauri et al., 1998; Levine et al., 2000; Mitani et al., 2006). A 
single nucleotide polymorphism (SNP) in metabotropic 7 glutamate receptor was 
shown to be involved in the onset of the clinical antidepressant effect (Fabbri et al., 
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2013). Glutamate release decreases with chronic fluoxetine, desipramine, reboxetine, 
venlafaxine or agomelatine treatment (Bonanno et al., 2005; Musazzi et al., 2010). 
Numerous studies have shown that chronic antidepressant treatment regulates 
glutamatergic receptor expression in rodent hippocampus (Boyer et al., 1998; 
Skolnick, 1999; Martinez-Turrillas et al., 2002; Barbon et al., 2006; Pittaluga et al., 
2007; Wieronska et al., 2007; Ryan et al., 2009; Calabrese et al., 2012; O' Connor et 
al., 2013). The current study also indicates that NRs and P-NRs expression levels 
were differentially affected in paroxetine-treated sub-groups.  
We also observed different levels of proteins downstream of the glutamate receptor 
(CaMKII, GSK-3β, P-ERK), which might be a reflection of differential NMDA 
receptor activity. CaMKII has been linked to neurotransmitter release and synaptic 
plasticity (Lotrich and Pollock, 2005), which has been associated with 
neuropsychiatric disorders and antidepressant treatment effects (Pavlides et al., 2002; 
Holderbach et al., 2007; Wang et al., 2008). Our observation of a lower CaMKII 
expression level in PSF mice suggests a regulatory mechanism that prevents synaptic 
connections becoming too strong as has been suggested by Robison et al (Robison et 
al., 2014). 
Accumulating evidence has implicated GSK-3 in the pathogenesis of bipolar disorder 
and major depressive disorder (Gould et al., 2004; Lovestone et al., 2007) as well as 
the antidepressant treatment response. Tsai et al., reported that polymorphisms in 
GSK-3β gene were associated SSRI treatment response (Tsai et al., 2008). Paroxetine 
and lithium treatments were shown to regulate GSK-3β phosphorylation which also 
predicts clinical improvement of depressive patients (Gassen et al., 2016). Joaquim et 
al. showed that long-term treatment with sertraline induces increased expression and 
decreased phosphorylation of GSK-3β in MDD patient platelets (Joaquim et al., 2012). 
Our chronic paroxetine treatment did not induce significantly different inhibition of 
GSK-3β activity, which is evident from Ser9-P-GSK-3β protein levels. As GSK-3 
protein suppresses Ca
2+
-current and neurotransmitter release by inhibiting calcium 
channels and soluble NSF attachment protein receptor (SNARE) complex interaction 
(Wildburger and Laezza, 2012), low levels of GSK-3β total protein in PSF mice 
might result in greater synaptic transmission and a more favourable antidepressant 
treatment outcome.  
Several lines of evidence have also associated ERK with MDD and the antidepressant 
treatment response. Post-mortem brains of depressed suicide subjects showed reduced 
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ERK expression suggesting a role of the protein in MDD pathophysiology (Dwivedi 
et al., 2001). Antidepressant treatment increases ERK phosphorylation levels in 
rodent hippocampus (Gourley et al., 2008; Qi et al., 2008). Different P-ERK levels 
between PLF and PSF mice implicate a potential role in the heterogeneous 
antidepressant treatment response. 
We also observed significantly different GDH1 and SYNJ1 protein levels between 
PLF and PSF groups. GDH1 has been associated with glutamatergic transmission and 
synaptic activity in the hippocampus (Bao et al., 2009; Michaelis et al., 2011). In 
addition, SYNJ1 gene expression, which is required for vesicle recycling and synaptic 
transmission (Cremona et al., 1999; Lüthi et al., 2001; Kim et al., 2002; Mani et al., 
2007) was reported to be significantly altered by imipramine and St John’s wort, an 
herbal product with antidepressant activities (Wong et al., 2004). GDH1 and SYNJ1 
protein level alterations may indicate different synaptic transmission activity between 
PLF and PSF groups.  
My results were further corroborated by metabolite profiling data. GDH1 catabolizes 
glutamate and its elevated levels may be caused by the low GDH1 protein expression 
I found in PSF mice. Alternatively, high glutamate levels might induce a 
compensatory feedback regulation of GDH1 protein expression to prevent pathway 
over-activation. Altered NR levels are consistent with the observed glutamate levels 
in the PLF and PSF mice. More glutamate and other NMDA receptor modulators 
could result in reduced NMDA receptor expression as previously reported in studies 
with L-trans-pyrrolidine-2,4-dicarboxylate, a high-affinity glutamate reuptake 
inhibitor (Cebers et al., 1999; 2001).  
In particular PSD-95 and nNOS, which functionally interact with NMDA receptor 
(Bredt and Snyder, 1989; Vallebuona and Raiteri, 1994; Fedele et al., 2001) and 
produce NO, are of great interest with regard to the heterogeneous antidepressant 
response. Hippocampal nNOS was found to mediate glucocorticoid-induced 
depressive behavior in mice (Zhou et al., 2011) and the number of nNOS-
immunoreactive neurons in post-mortem hippocampus samples was higher in MDD 
and bipolar disorder patients compared to the control group (Oliveira et al., 2008). 
Plasma NO metabolite levels were higher in MDD patients compared to healthy 
controls, which was reversed by 8 week paroxetine treatment (Chrapko et al., 2006).  
NO has also been implicated to play a role for the function of antidepressant-like 
agents tramadol, bupropion and lithium (Dhir and Kulkarni, 2007; Ghasemi et al., 
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2008; Jesse et al., 2008). Serotonergic antidepressants including citalopram, 
imipramine, paroxetine and tianeptine have been shown to decrease hippocampal 
NOS activity in vitro and in vivo (Finkel et al., 1996; Wegener et al., 2003). Based on 
these findings targeting the NO system is a potential therapeutic strategy for major 
depressive disorders. Doucet et al., reported that a single administration of PSD-
95/nNOS interface inhibitors, IC87201 and ZL006, produced an antidepressant-like 
effect in the FST and tail suspension test (TST) (Doucet et al., 2013). In addition, 
nNOS inhibitors like Nω-Propyl-L-Arginine, 7-nitroindazole and aminoguanidine 
have been shown to produce antidepressant-like effects (Joca and Guimarães, 2006; 
Zhou et al., 2007; Hiroaki-Sato et al., 2014; Tomaz et al., 2014). I found that the 
hippocampal NMDA receptor/PSD-95/nNOS protein complex was expressed at 
significantly different levels between PLF and PSF mice, implying that it has an 
important role in the chronic antidepressant treatment response. 
We also investigated CAPON and sGC-β1, proteins associated with the NO pathway, 
to further corroborate the differential activity of the NMDA receptor/PSD-95/nNOS 
protein complex between PLF and PSF groups. CAPON has been shown to disrupt 
the interaction between nNOS and postsynaptic proteins including PSD-95, which 
prevents NMDA receptor-mediated NO release (Xu et al., 2005). I found high levels 
of hippocampal CAPON protein in PSF mice which may contribute to a favorable 
antidepressant treatment response, possibly by suppressing nNOS activity.  
sGC-β1 protein levels between PLF and PSF mice were not significantly different, 
which is in line with results from Reierson et al. who reported that 8-weeks of SSRI 
fluoxetine treatment did not change sGC-β1mRNA levels in rat hippocampus 
(Reierson et al., 2009). It has been also shown that sGC-β1mRNA levels were not 
affected in human schizophrenic prefrontal cortex post-mortem samples that had 
higher nNOS mRNA levels compared to controls (Baba et al., 2004). Although I did 
not find sGC-β1protein expression level differences, I cannot exclude the possibility 
that sGC enzymatic activity might be different between PLF and PSF groups. 
Consistent with nNOS protein levels, citrulline levels between PLF and PSF mice 
were alos altered after 28 days of paroxetine treatment. Since nNOS catalyzes the 
production of NO and citrulline from arginine, lower levels of citrulline in PSF mouse 
hippocampus may indicate lower enzymatic nNOS activity. 
Hippocampal metabolome profiling also supported differential NMDA receptor 
activity between the two groups. Alanine and citrate are known to regulate NMDA 
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receptor activity. (Westergaard et al., 1995; Popescu et al., 2010) Glutathione is an 
NMDA receptor agonist (CHUEH, 2006; Rosa et al., 2013) and sarcosine is an 
NMDA receptor co-agonist (Zhang et al., 2009; Huang et al., 2013). The role of 
serine as a potent co-agonist of NMDA receptor has been demonstrated.(Mothet et al., 
2000; Panatier et al., 2006) In addition, taurine is suggested to interact directly with 
NMDA receptor and regulates its function (Suárez and Solís, 2006).  
Maes et al. found that low serum levels of asparagine, serine and taurine levels 
characterized non-responder patients after 5-weeks of antidepressants treatment 
(Maes et al., 1998). In addition, glutathione, sarcosine and taurine administration have 
antidepressant-like effects suggesting the here found elevated levels might be relevant 
for the favorable paroxetine response (Huang et al., 2013; Rosa et al., 2013; Toyoda 
and Iio, 2013). 
The different glutamatergic pathway activity is also reflected in MDD patients’ 
PBMCs by the observed sGC-β1 protein levels, which is downstream of the 
glutamatergic pathway. 
Taken together, my study suggests that monitoring glutamatergic pathway protein and 
metabolite levels can be used to determine whether paroxetine-treated patients with 
depressive disorders are responding to the drug.   
 
4.3. Ubiquitin-proteasome system pathway 
No significant mRNA level differences for NRs, PSD-95 and nNOS were found 
between PLF and PSF groups suggesting that post-translational modifications might 
be relevant instead. Supporting this notion I found proteomics signatures involved in 
the UPS pathway that significantly differed between the two groups. While my data 
indicate that ubiquitination is not associated with differential protein expression levels 
in paroxetine-treated mice, PM2A protein and total ubiquitination level differences 
suggest potential roles in the antidepressant treatment response.  
Protein analyses of PBMCs showed that UBS pathway components including PM2A 
and ubiquitination can separate antidepressant treatment responder/non-responder 
patients. Especially PM2A levels were significantly lower at T6 only in 
antidepressant responder patients and could be used to monitor and determine the 
antidepressant treatment response. In addition, ubiquitination at baseline may be used 
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to predict the response to antidepressant treatment, as its levels stayed low in 
antidepressant responder patients at T0 and T6 compared to non-responder patients. 
Evidence from other studies suggests that the UPS may be linked to MDD treatment. 
In this regard, it has been shown that SNPs in proteasome subunit α7 (PSMA7), 
proteasome 26S non-ATPase subunit 9 (PSMD9) and proteasome 26S non-ATPase 
subunit 13 (PSMD13) are associated with clinical antidepressant response (Wong et 
al., 2008; Gragnoli, 2014). Data from my thesis project suggest that UPS protein 
signatures such as PM2A and ubiquitination levels could be used to assess 
antidepressant treatment outcome. Especially ubiquitination levels at baseline may be 
able to predict the response to antidepressant treatment. As stressful events are known 
to alter the UPS pathway (Ryan et al., 2006; Karssen et al., 2007; Minelli et al., 2015), 
higher ubiquitination levels in antidepressant non-responder patients might be a 
reflection of that. Despite the fact that data from the present study failed to show a 
significant correlation between baseline ubiquitination levels and clinical 
antidepressant treatment response (Figure 55), the inclusion of larger sample size may 
increase predictability power of the analysis.   
 
 
Figure 55. Correlation between baseline ubiquitination levels and clinical antidepressant 
response. Baseline ubiquitintion levels did not show significant correlation with HDRS score 
changes after treatment. Pearson correlation coefficients (r) with P values are indicated in the 
correlation graphs. 
 
UPS was shown to be involved in the regulation of various neuronal pathways 
including synaptic formation and function (Yi and Ehlers, 2007). In light of this, 
significant differences of PM2A and ubiquitination levels between antidepressant 
responder and non-responder mice and humans implicate a potential involvement of 
systemic molecular pathways. For example, UPS has been shown to mediate NMDA 
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receptor degradation (Kato et al., 2005; Yi and Ehlers, 2007; Tsai, 2014). Tai et al. 
reported that NMDA treatment of cultured hippocampal neurons decreases UPS 
activity, suggesting an interaction between glutamatergic and proteasome pathways 
(Tai et al., 2010). This is in agreement with my data, which also point towards an 
involvement of both pathways in the different response of the PLF and PSF mouse 
groups. Although my results indicate that ubiquitination does not seem to be 
associated with the regulation of NMDA receptor/PSD-95 protein levels in the 
paroxetine-treated mice, my proteomics analysis significantly enriched the UPS 
pathway (Figure 56). The relationship of UPS and glutamatergic pathways is of 
interest and should be further explored in the future.  
 
 
Figure 56. A heatmap of hippocampal UPS pathway proteins comparing PLF and PSF groups. 
In the heatmap, colors denote log2 ratio. Proteins with adjusted p value < 0.05 were considered 
significant, n=5/group. 
 
Kaminsky and Kosenko showed that MK-801, an NMDA receptor blocker, and 
sodium nitroprusside, an NO donor, were able to modulate brain purine metabolism 
activity suggesting a functional involvement of NMDA receptor and nitric oxide in 
purine metabolism pathway (Kaminsky and Kosenko, 2009). GDA, which catalyzes 
conversion of guanine to xanthine in the purine metabolism pathway (Yuan et al., 
1999; Paletzki, 2002), was found to be important for neuronal dendrite branching by 
regulating postsynaptic trafficking of PSD-95 protein, a major component of the 
glutamatergic synapse (Firestein et al., 1999). Antidepressant-like and neuroprotective 
effects of pyrimidines including cytidine and uridine have been linked to the 
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regulation of glutamatergic neurotransmission  (Mir et al., 2003; Hurtado et al., 2005; 
Radad et al., 2007; Yoon et al., 2009). In this context, illuminating the crosstalk 
between purine/pyrimidine metabolism and glutamatergic pathways may aid in an 
improved understanding of their functions in the pathobiology of MDD and its 
treatment. 
Whether the pathways I have identified in the mouse will qualify as predictive 
biosignatures for the antidepressant treatment response in patients and routine use in 
the clinic remains to be further investigated. Eventually biomarkers for the 
antidepressant treatment response will enable patient sub-group stratification and will 
render clinical decision making more objective to realize a personalized psychiatry 
approach.  
 
4.4. Outlook 
This study aimed at the molecular delineation of the chronic antidepressant treatment 
response in mice, and validation in MDD patients’ PBMCs. While my integrated -
omics analyses of the hippocampus revealed novel pathways and biomarker 
candidates, additional analyses of other brain regions that are implicated in 
neuropsychiatric disorders may provide a more systemic understanding related to the 
antidepressant response heterogeneity. 
As shown in previous reports several metabolites seem to play a role in the regulation 
of mood status and have potential to be used as supplements in treating psychiatric 
disorders (Papakostas et al., 2012; Foster and McVey Neufeld, 2013; Slyepchenko et 
al., 2014). Based on the dynamic changes of the metabolome in response to 
antidepressant treatment, the effect of nutritional supplements are also of great 
interest. 
Conventional mental disorder diagnosis systems may benefit from Research Domain 
Criteria (RDoC), a new research framework initiated by the U.S. National Institute of 
Mental Health. Integration of multi-dimensional data from genomics to clinical 
reports can reduce the gap between molecular research and clinical practice, and 
therefore is expected to provide new evidence and perspectives on classification and 
treatment decision of neuropsychiatric disorders. 
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